

HANNA PHAN, PHARMD, FCCP, FPPA

428 Church Street, North University Building Office 3568

Ann Arbor MI 48109

734-647-9044 (Office)

Email: hphan@med.umich.edu

Last Updated: November 3, 2024

EDUCATION

UNDERGRADUATE AND GRADUATE/PROFESSIONAL EDUCATION:

Doctor of Pharmacy (with Distinction) College of Pharmacy University of Michigan Ann Arbor, Michigan	1999 – 2003
Pre-Pharmacy College of Literature, Science, and Arts University of Michigan Ann Arbor, Michigan	1997 – 1999

POST-GRADUATE TRAINING:

Postdoctoral Fellowship in Pediatric Pharmacotherapy Fellowship Director: Milap C. Nahata, PharmD, MS, FCCP, FPPA The Ohio State University, College of Pharmacy, Nationwide Children's Research Institute Columbus, Ohio	2006 – 2008
---	-------------

PROFESSIONAL DEVELOPMENT:

Mid-Career Faculty Recharge American Association of Colleges of Pharmacy (AACCP)	2023 – 2024
Health Sciences Teaching Academy (HSTA) University of Michigan, Center for Interprofessional Education	2023
Interprofessional Leadership Fellow <i>Cohort 6 - Area of Focus: Experiential Education</i> University of Michigan, Center for Interprofessional Education	2021-2022
Leadership and Management Certificate Program American College of Clinical Pharmacy (ACCP)	2016 – 2018
Quality Improvement Training Cystic Fibrosis Foundation and Dartmouth Institute	2015 – 2016
Clinical & Translational Research Graduate Certificate Mel and Zuckerman College of Public Health University of Arizona Tucson, Arizona	2010 – 2012

<p>Focused Investigator Training (FIT) American College of Clinical Pharmacy (ACCP) Research Institute Salt Lake City, Utah</p>	2009
<p>Teaching Certificate The Ohio State University</p>	2006 – 2009

LICENSURE AND CERTIFICATIONS

Arizona – Registered Pharmacist Licensure	2008 – Present
Ohio – Registered Pharmacist Licensure	2007 – Present
Michigan – Registered Pharmacist Licensure	2003 – Present

PROFESSIONAL AND ACADEMIC POSITIONS

ADMINISTRATIVE/LEADERSHIP:

<p>Director, Office of Experiential Education University of Michigan – College of Pharmacy Ann Arbor, Michigan</p>	9/2024 – Present
<p>Assistant Department Head Department of Pharmacy Practice and Science University of Arizona College of Pharmacy Tucson, Arizona</p> <ul style="list-style-type: none"> ▪ Oversee department faculty mentoring program ▪ Point of contact/liaison for clinical practice site supervisors (Banner Health, El Rio Community Health Centers) ▪ Implemented team-centered process for revision of department metrics based on updated university and college strategic plan, finalized department metrics with department head ▪ Developed and implement annual department retreat 	10/2018 – 8/2020
<p>Residency Program Director Postgraduate Year 2 (PGY2) Pediatric Pharmacy Residency Program Banner University Medical Center – Tucson, Diamond Children’s Tucson, Arizona</p> <ul style="list-style-type: none"> • Established the 1st pediatric PGY2 residency program in Arizona • Successful full accreditation during tenure as RPD 	11/2009 – 6/2015

ACADEMIC:

<p>Faculty Affiliate, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center Michigan Medicine, Division of General Pediatrics Ann Arbor, Michigan</p>	4/2021 – Present
<p>Clinical Associate Professor Department of Clinical Pharmacy University of Michigan – College of Pharmacy Ann Arbor, Michigan</p>	8/2020 – Present

Associate Professor (Designated Campus Colleague, Adjunct) Department of Pharmacy Practice and Science University of Arizona – College of Pharmacy Tucson, Arizona	9/2020 – 9/2022
Clinical Associate Professor (Adjunct Appointment) Department of Clinical Pharmacy University of Michigan College of pharmacy Ann Arbor, Michigan	8/2018 – 8/2020
Associate Research Scientist (Joint Appointment) Asthma and Airway Disease Research Center (A2DRC) University of Arizona Tucson, Arizona	4/2017 – 8/2020
Associate Professor (Joint Appointment) Section of Pediatric Pulmonary and Sleep Medicine Department of Pediatrics University of Arizona College of Medicine Tucson, Arizona	7/2016 – 8/2020
Associate Professor Non-Tenure Eligible, 2016-2017; Tenure-Eligible, 2017-2020 Department of Pharmacy Practice and Science University of Arizona College of Pharmacy Tucson, Arizona	7/2016 – 8/2020
Assistant Scientist (Joint Appointment) Asthma and Airway Disease Research Center (A2DRC) (Formally known as Arizona Respiratory Center) University of Arizona Tucson, Arizona	5/2015 – 4/2017
Assistant Professor (Joint Appointment) Section of Pediatric Pulmonary and Sleep Medicine Department of Pediatrics University of Arizona College of Medicine Tucson, Arizona	8/2010 – 6/2016
Faculty, Pharmacy Discipline Pediatric Pulmonary Center (MCHB Funded) University of Arizona College of Medicine Tucson, Arizona	8/2009 – 8/2020
Assistant Professor (Non-Tenure Eligible) Department of Pharmacy Practice and Science University of Arizona College of Pharmacy Tucson, Arizona	8/2008 – 6/2016

CLINICAL PRACTICE:

Clinical Pharmacist Specialist, Ambulatory Care Pharmacy Innovations & Partnerships, Michigan Medicine Pediatric Cystic Fibrosis Center C.S. Mott Children’s Hospital, Michigan Medicine Ann Arbor, Michigan	8/2020 - Present
Clinical Pharmacy Specialist Pediatric Cystic Fibrosis Center, Pediatric Severe Asthma Clinic; Adult Cystic Fibrosis Center Diamond Children’s, Banner University Medical Center – Tucson Tucson, Arizona	8/2008 – 8/2020
Pediatrics/Neonatal ICU Clinical Staff Pharmacist C.S. Mott Children’s Hospital University of Michigan Health System Ann Arbor, Michigan	10/2004 – 6/2006
Clinical Pharmacist Heartland Home Care and Hospice Livonia, Michigan	10/2003 – 10/2004
Staff Pharmacist Southeast Michigan District (Detroit South); Walgreens Co.	7/2003 – 10/2003

CONSULTATIVE:

Consultant, Clinical Specialist Wolters Kluwer, Lexicomp (Pediatric and Neonatal Lexi-Drugs)	2/2018 – Present
---	------------------

HONORS AND AWARDS

2022	Recipient , PGY2 Pediatric Pharmacy Preceptor of the Year, Michigan Medicine
2019	Recipient , ACCP Pediatric Practice and Research Network Achievement Award Recognizes one full ACCP and member of the Pediatric PRN (≥ 10 years) annually who: <ul style="list-style-type: none"> ▪ Demonstrated leadership in pediatric pharmacy ▪ Sustained a high level of contribution related to practice, education, research, service, and/or advocacy in pediatric pharmacy ▪ Has maintained a high level of active service and contributions within ACCP and the Pediatric PRN.
2018	Fellow (FPPA) , Pediatric Pharmacy Association (PPA)
2016	Fellow (FCCP) , American College of Clinical Pharmacy (ACCP)
2016	Recipient , Theodore G. Tong Distinguished Leadership and Service Award The University of Arizona College of Pharmacy

- 2015 **Recipient**, Presidential Citation Award
Pediatric Pharmacy Association (PPA)
- 2014 **Recognition for Service**, Research Committee
Pediatric Pharmacy Association (PPA)
- 2012 **Recipient**, Exemplary Patient Care Award
Arizona Pharmacy Association
- 2012 **Recipient**, Spirit of PPA Award
Pediatric Pharmacy Association (PPA)
- 2009 **Co-Recipient**, Pharmacy Practice Literature Award
ASHP Research and Education Foundation
Kaakeh Y, Phan H, DeSmet B, Pasko DA, Glenn DK, Stevenson JG. Enhanced photoemission spectroscopy for verification of high-risk intravenous medications. Am J Health Syst Pharm. 2008; 65(1):49-54.
- 2007 **Honorary Mention**, President’s Salute for Teaching, Undergraduate Programs
The Ohio State College of Pharmacy, College of Pharmacy

AWARDED GRANTS / EXTRAMURAL FUNDING

(*denotes trainee(s) supervised by Dr. Phan)

Principal Investigator or Co-Principal Investigator Grants

- 2019 “Complementary Alternative Medicine (CAM), Cannabis, and Therapeutic Diets in Cystic Fibrosis (CF): Perspectives of Persons with CF, Caregivers of Infants/Children/Adolescents with CF, and CF Healthcare Providers,” from Arizona Area Health Education Center, The University of Arizona College of Pharmacy Health Disparities Grant.
\$1,440, funding for participant gift card raffle
Collaborators: Lam M*, Bradshaw S, Anderson K*, Bowen A, Sharpe A, Jackson K, Hall-Lipsy E, Anderson K*
Role: Principal Investigator
- 2019 “Medication Education in Cystic Fibrosis (CF) Care Centers: Perspectives of Persons with CF, Caregivers of Infants/Children/Adolescents with CF, and CF Healthcare Providers,” from Arizona Area Health Education Center, The University of Arizona College of Pharmacy Health Disparities Grant.
\$480, funding for participant gift card raffle
Collaborators: Seto D*, Romero-Aleshire J*, Eastep TG*, Bowen A, Sharpe A, Hall-Lipsy E
Role: Principal Investigator
- 2018 – 2020 “Success with Therapies Research Consortium CF Center Grant,” from Cystic Fibrosis Foundation.
\$50,000, 5% effort (0.6 calendar months)
Collaborator: Daines CL
Role: Co-Principal Investigator

- 2016 – 2020 “Feasibility of a Mobile Medication Plan Application in CF Patient Care,” from Success with Therapies Research Consortium (STRC) Pilot/Feasibility Award, Cystic Fibrosis Foundation, MAP16PEO.
\$850,000, 25% effort (3 calendar months)
Collaborators: Daines CL (Co-PI)
Role: Co-Principal Investigator
- 2016 – 2019 “Expansion of Pharmacy Services in Accredited Adult and Pediatric Cystic Fibrosis (CF) Clinics,” from Cystic Fibrosis Foundation.
\$200,880, 10% effort (1.2 calendar months)
Collaborators: Daines CL (Co-PI)
Role: Co-Principal Investigator
- 2016 – 2017 “Perspectives of Rural and Non-Rural Community Pharmacists in Pediatric Dosing and Recommendations,” from Arizona Area Health Education Center, The University of Arizona College of Pharmacy Health Disparities Grant.
\$2,042 (for subject incentives, travel)
Collaborators: Hall-Lipsy (Co-PI), Hu J*, Lin G*
Role: Principal Investigator
- 2014 – 2018 “Success with Therapies Research Consortium CF Center Grant,” from Cystic Fibrosis Foundation.
\$75,000, 5% (0.6 calendar months)
Collaborator: Daines CL (Co-PI)
Role: Co-Principal Investigator
- 2014 – 2018 “Success with Therapies Research Consortium CF Center Grant,” from Cystic Fibrosis Foundation.
\$75,000, 5% (0.6 calendar months)
Collaborator: Daines CL (Co-PI)
Role: Co-Principal Investigator
- 2014 – 2016 “Pharmacist Collaborative Practice in the Management of High-Risk Pediatric Asthma,” from American Society of Health-System Pharmacists (ASHP) Research and Education Foundation, New Investigator Grant.
\$19,967, 1.5% effort (0.18 calendar months)
Collaborators: Brown MA, Erstad BL
Role: Principal Investigator
- 2011 “Gender-Associated Perceived Biases of Pharmacy Faculty,” from The University of Arizona ADVANCE Program, Seed Grant.
\$5,500 (funding for project supplies and travel)
Collaborator: Matthias KR
Role: Principal Investigator
- 2011 “Translation of School-Based, Supervised Asthma Therapy into an Internet-Based, Clinician Tool,” from Health Resources and Services Administration, Maternal and Child Health Training Grant T76MC04925.
\$5000, funding for application development
Collaborator: Gerald LB (Co-PI)
Role: Co-Principal Investigator

2007 “Prescribing trends for medications in the treatment of adolescents and young adults with Type 2 diabetes mellitus” from Takeda Pharmaceutical Company Ltd., Investigator Initiated Grant.
 \$74,000, 10% effort (1.2 calendar months).
 Collaborators: Nahata MC (PI), Porter K
 Role: Co-Principal Investigator

Co-Investigator Grants/Subcontracts

2024-2026 “Success with Therapies Research Consortium CF Center Grant”, from Cystic Fibrosis Foundation, BUTCHE14PE0-STRC
 \$47,040, 2.1% effort (0.252 calendar months)
 Collaborator: Butcher J (Co-PI), Nasr SZ (Co-PI)
 Role: Co-Investigator

2023 – 2024 “Therapeutic Development Center Award,” from Cystic Fibrosis Foundation, 002968Y121.
 \$2,237,600, 5-17% effort (0.6-2.04 calendar months)
 Collaborator: Nasr SZ (PI)
 Role: Sub-Investigator

2023 “Success with Therapies Research Consortium CF Center Grant”, from Cystic Fibrosis Foundation, BUTCHE14PE0.
 \$47,876, 13.65% effort (1.64 calendar months)
 Collaborator: Butcher J (Co-PI), Nasr SZ (Co-PI)
 Role: Co-Investigator

2021 “Cystic Fibrosis Center Grant,” from Cystic Fibrosis Foundation, 000592CC323.
 \$1,664,155, 5% effort (0.6 calendar months)
 Collaborator: Nasr SZ (PI)
 Role: Sub-Investigator

2020 – 2023 “Expansion of Outpatient Pharmacy Services in Cystic Fibrosis (CF) Clinics,” from Award for a Pharmacist and/or Technician Grant. Cystic Fibrosis Foundation, CCRX184-19.
 \$168,480, 30-43% effort (3.6-5.16 calendar months)
 Collaborator: Nasr SZ (PI)
 Role: Co-Investigator, Clinician, Clinical Pharmacist Specialist

2017 – 2023 “An Asthma Collaboration to Reduce Childhood Asthma Disparities on The Navajo Nation,” from National Heart, Lung, and Blood Institute (NHLBI), U01 HL138689-010.
 \$4,598,574, 10% effort (1.2 calendar months for 2017-2020), 2.5% (0.3 calendar months for 2021-2023)
 Collaborators: Gerald LB (Co-PI), Bender BG (Co-PI), King D, Kobernick A, Liu A, Morgan WJ, Nez P, Simmons B, Lowe A, Solomon T.
 Role: Co-Investigator

2017 – 2019 “Implementation of the Depression and Anxiety Guidelines: Award for A Mental Health Coordinator,” from Cystic Fibrosis Foundation.
 \$150,000, 2% effort (0.24 calendar months)
 Collaborators: Daines CL (PI), Bowen AL, McGuire M, Mees L
 Role: Sub-Investigator

- 2015 – 2020 “Pediatric Pulmonary Center Training Grant,” from Health Resources and Services Administration (HRSA), Maternal Child Health Bureau (MCHB), T72MC00012.
\$1,693,642, 8% effort (0.96 calendar months)
Collaborators: Brown MA (PI until July 2016), Daines CL (PI from July 2016), Rascon L, Settle P, McGuire M
Role: Sub-Investigator
- 2015 – 2016 “Redesigning clinic workflow to improve outpatient cystic fibrosis care,” from Cystic Fibrosis Foundation, Quality Improvement Project Grant.
\$24,000 (for travel support and Dartmouth Quality Improvement Training)
Collaborators: Daines CL (PI), Drake G, McGuire M, Parker M, Settle P, Werchan B, Champion J, Ojo T.
Role: Co-Investigator
- 2011 – 2014 “Integrating Pharmacy Practice Residents and Student Pharmacists into Practice to Promote Innovative Pharmacy Services in San Luis,” from Arizona Area Health Education Centers (AHEC), Training Center Grant.
\$615,819, 5% (0.6 calendar months)
Collaborators: Kennedy AK (PI), Matthias KR
Role: Co-Investigator
- 2011 – 2013 “Redesigning Inpatient Cystic Fibrosis Care,” from Cystic Fibrosis Foundation, Quality Improvement Project Grant.
\$50,000, 2% effort (0.24 calendar months)
Collaborators: Daines CL (PI), Drake G, McGuire M, Parker M, Settle P, Werchan B
Role: Co-Investigator
- 2010 – 2015 “Pediatric Pulmonary Center Training Grant,” from Health Resources and Services Administration (HRSA), Maternal Child Health Bureau (MCHB), T72MC00012.
\$1,693,642, 10% effort (1.2 calendar months)
Collaborators: Brown MA (PI), Rascon L, Settle P, McGuire M
Role: Sub-Investigator

Grants / Contracts – Under Review

- 2024-2026 Michigan CF Health Disparities Learning Program (MI-CF HELP),” from Cystic Fibrosis Foundation.
\$150,000, 5% effort (0.6 calendar months)
Collaborators: Nasr SZ (PI), Filbrun A, Caverly LC, Enochs C
Role: Co-Investigator

Grants / Contracts – Unfunded

- 2023 “Integrating Data for Enhanced CF Care Partnership (IDEP-CF),” from Cystic Fibrosis Foundation from Cystic Fibrosis Foundation
\$662,700, 25% effort (3 calendar months)
Collaborators: Gutierrez H (Co-PI), Nasr SZ, Ruiz F
Role: Co- Principal Investigator
- 2022 “Comparison and Collaboration of Hybrid Telehealth Models in the Delivery of Interprofessional, Patient-Focused Pediatric Cystic Fibrosis (CF) Care,” from Cystic Fibrosis Foundation

\$537,458, 13% effort (1.56 calendar months)
 Collaborators: Nasr SZ, Daines CL, Autry E.
 Role: Principal Investigator

2022 “Integrating Data for Engaged CF Care (IDEA),” from Cystic Fibrosis Foundation
 \$275,202, 15% effort (1.8 calendar months)
 Collaborators: Oates G (PI), Gutierrez H, Nasr SZ.
 Role: Principal Investigator

2013 “Pharmacist Collaborative Practice in the Management of High-Risk Pediatric Asthma,”
 from American Society of Health-System Pharmacists (ASHP) Research and Education
 Foundation, New Investigator Grant.
 \$20,000, 2% effort (0.24 calendar months)
 Collaborators: Brown MA, Erstad BL
 Role: Principal Investigator

PUBLICATIONS

(Key: *denotes student, resident, or postdoc at the time)

Web of Science Researcher ID: E-1476-2016 (*as of Aug 10, 2024*: h-index = 12)

Google Scholar (*as of Oct 31,, 2024*: h-index = 17, i10 index = 20)

ORCID ID: 0000-0003-4968-1460

Peer-Reviewed Publications

Published

Cited Source: Google Scholar (as of August 10, 2024: h-index = 16 and i10 index = 20)

Key: *denotes student, resident, or postdoc at the time; N/A=not available

41. **Phan H**, Daines CL, Woo T, Psoter KJ, Goodman A, McWilliams E, Frederick C, Milla C, Oates G, Sawicki GS, Riekert KA. Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ). *J Cyst Fibros*. 2024 Jun 7:S1569-1993(24)00073-0. doi: 10.1016/j.jcf.2024.05.011. Epub ahead of print. PMID: 38851920.
 Journal Impact Factor: 4.8, Times Cited: 0
 Role: conceptualization, design, writing, critical review, corresponding author
40. Bender BG, Crooks J, Gerald JK, Hudson B, King DK, Kobernick A, Liu AH, Lowe AA, Morgan W, Nez P, **Phan H**, Wightman P, Gerald LB. Childhood asthma exacerbations on the Navajo Nation. *J Allergy Clin Immunol Pract*. 2024 Apr 30:S2213-2198(24)00429-X. doi: 10.1016/j.jaip.2024.04.044. Epub ahead of print. PMID: 38697473.
 Journal Impact Factor: 11.1, Times Cited: 0
 Role: design, critical review
39. Hovey S, Tabulov C, Matson K, **Phan H**. Age-Based Transitions of Care: Where is the Pharmacist? *J Am Coll Clin Pharm*. 2024;7:523–528. doi.org/10.1002/jac5.1962.
 Journal Impact Factor: 1.3, Times Cited: 0
 Role: conceptualization, design, writing, critical review, corresponding author
38. Kadouh* NK, Elijah* J, Fitzgerald LJ, **Phan H**. Use of CFTR modulators in special populations, part 3: Solid organ transplant. *Pediatr Pulmonol*. 2023 Dec;58(12):3393-3402. doi: 10.1002/ppul.26396. Epub 2023 Apr 17. PMID: 37067449.
 Journal Impact Factor: 2.7, Times Cited: 1
 Role: conceptualization, design, analysis, critical review, corresponding author

37. Elijah* J, Fitzgerald LJ, **Phan H**. Use of CFTR modulators in special populations, part 2: Severe lung disease. *Pediatr Pulmonol*. 2023 Dec;58(12):3386-3392. doi: 10.1002/ppul.26698. Epub 2023 Sep 20. PMID: 37728222.
Journal Impact Factor: 2.7, Times Cited: 1
Role: conceptualization, design, analysis, critical review, corresponding author
36. Elijah* J, Fitzgerald LJ, **Phan H**. Use of CFTR modulators in special populations, part 1: Pregnancy and lactation. *Pediatr Pulmonol*. 2023 Dec;58(12):3377-3385. doi: 10.1002/ppul.26706. Epub 2023 Oct 3. PMID: 37787417.
Journal Impact Factor: 2.7, Times Cited: 3
Role: conceptualization, design, analysis, critical review, corresponding author
35. Kim AS*, Thompson AN, Axon DR, Sabourin A, Davies MJ*, Shannon C, Nasr SZ, **Phan H**. A scoping review of clinical pharmacist and pharmacy technician contributions to cystic fibrosis care. *J Am Coll Clin Pharm*. 2023; 1-9. doi:10.1002/jac5.187.7.
Journal Impact Factor: 1.3, Times Cited: 1
Role: conceptualization, design, analysis, writing, critical review, corresponding author
34. Anderson K*, Gerald LB, Hall-Lipsy E, McCulley K, Vuong E, **Phan H**. Pharmacists' Perspectives on Inhaled Bronchodilator Use and Stock Inhaler Access for School-Age Children. *J Public Health Policy*. 2023 Sep;44(3):464-476. doi: 10.1057/s41271-023-00423-8. Epub 2023 Jun 21. PMID: 37344541.
Journal Impact Factor: 2.3, Times Cited: 0
Role: conceptualization, design, analysis, writing, critical review, corresponding author
33. Reeves, SL, Dombkowski, KJ, Peng, HK, **Phan H**, Kolenic, G, Creary, SE, Madden, B, Lisabeth, LD. Adherence to Hydroxyurea and Clinical Outcomes among Children with Sick Cell Anemia. *Pediatr Blood Cancer*. 2023 Apr 12: e30332. doi: 10.1002/pbc.30332. Epub 2023 Apr 12. PMID: 37046404.
Journal Impact Factor: 2.4, Times Cited: 6
Role: writing, critical review
32. Ince HY*, **Phan H**, Nasr SZ, Pierce JM, Malas N. Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis. *Pediatr Pulmonol*. 2023 Feb;58(2):398-407. doi: 10.1002/ppul.26241. Epub 2022 Nov 18. PMID: 36349504.
Journal Impact Factor: 2.7, Times Cited: 4
Role: conceptualization, design, writing, critical review
31. Lowe AA, Simmons B, Nez P, Begay E, Liu A, King D, Gerald JK, Aaron K, Wightman P, Solomon T, Crooks J, **Phan H**, Morgan W, Bender B, Gerald LB. An asthma collaboration to reduce childhood asthma disparities on the Navajo Nation: Trial protocol for the Community Asthma Program. *Public Health Pract (Oxf)*. 2022 Jul 21; 4:100289. doi: 10.1016/j.puhip.2022.100289. PMID: 36570396.
Journal Impact Factor: 2.2, Times Cited: 2
Role: design, critical review
30. Kimple AJ, Senior BA, Naureckas ET, Gudis DA, Meyer T, Hempstead SE, Resnick HE, Albon D, Barfield W, Benoit MM, Beswick DM, Callard E, Cofer S, Downer V, Elson EC, Garinis A, Halderman A, Hamburger L, Helmick M, McCown M, McKinzie CJ, **Phan H**, Rodriguez K, Rubenstein RC, Severin A, Shah G, Shenoy A, Sprouse B, Virgin F, Woodworth BA, Lee SE. Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. *Int Forum Allergy Rhinol*. 2022 Sep;12(9):1089-1103. doi: 10.1002/alr.22974. PMID: 35089650.
Journal Impact Factor: 7.2, Times Cited: 29
Role: design, analysis, critical review

29. Lowe AA*, **Phan H**, Hall-Lipsy E, O'Shaughnessy S, Nash B, Volerman A, Gerald LB. School stock inhaler statutes and regulations in the United States: a systematic review. *J Sch Health*. 2022; DOI: 10.1111/josh.13142. PMID: 35285022.
Journal Impact Factor: 1.8, Times Cited: 6
Role: conceptualization, design, analysis, writing, critical review

28. Enochs C, Filbrun AG, Iwanicki C, Moraniec H, Lehrmann J, Stiffler J, Dagher S, Tapley C, **Phan H**, Raines R, Nasr SZ. Development of an Interdisciplinary Telehealth Care Model in a Pediatric Cystic Fibrosis Center. *Telemed Rep*. 2021 Oct 12;2(1):224-232. doi: 10.1089/tmr.2021.0021. PMID: 35720757.
Journal Impact Factor: 1.5, Times Cited: 2
Role: design, writing, critical review

27. Volerman A, Lowe AA, Pappalardo AA, Anderson CMC, Blake KV, Bryant-Stephens T, Carr T, Carter H, Cicutto L, Gerald JK, Miller T, Moore NS, **Phan H**, Sadreameli SC, Tanner A, Winders TA, Gerald LB. Ensuring Access to Albuterol in Schools: From Policy to Implementation. An Official ATS/AANMA/ALA/NASN Policy Statement. *Am J Respir Crit Care Med*. 2021 Sep 1;204(5):508-522. PMID: 34499024.
Journal Impact Factor: 19.3, Times Cited: 13
Role: design, writing, critical review

26. Muirhead CA, Palmrose W, Condren M, Rotolo SM, Pettit RS, Gill M, **Phan H**. A clinician survey of use assessment, documentation, and education about cannabis in persons with cystic fibrosis. *Pediatr Pulmonol*. 2021 Sep;56(9):2879-2887. PMID: 34232573.
Journal Impact Factor: 2.7, Times Cited: 4
Role: analysis, writing, critical review

25. Muralidharan* P, Mallory* EK, Malapit* M, **Phan H**, Ledford JG, Hayes D, Mansour HM. Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols. *RSC Advances*. 2020;10(68):41846-56. PMID: 33391731.
Journal Impact Factor: 3.9, Times Cited: 16
Role: critical review

24. LaRochelle JM, Smith K, Benavides S, Bobo KS, Chung AM, Farrington E, Kennedy A, Knoppert D, Lee B, Manasco KB, Pettit R, **Phan H**, Potts AL, Sandritter TL, Hagemann T. Evidence demonstrating the pharmacist's direct impact on clinical outcomes in pediatric patients: An Opinion of the Pediatrics Practice and Research Network of the American College of Clinical Pharmacy. *J Am Coll Clin Pharm*. 2020; 3: 786– 792. doi.org/10.1002/jac5.1217.
Journal Impact Factor: 1.3, Times Cited: 3
Role: conceptualization, writing, critical review

23. Stranges PM, Jackevicius CA, Anderson SL, Bondi D, Danelich I, Englin EF, Hansen ML, Nys C, Patel RS, **Phan H**, Philibrick AM, Ranger M, Schumacher C, Smithgall S. Role of clinical pharmacists and pharmacy support personnel in transitions of care. *J Am Coll Clin Pharm*. 2020; 3:532–545. doi.org/10.1002/jac5.1215.
Journal Impact Factor: 1.3, Times Cited: 31
Role: design, analysis, writing, critical review

22. **Phan H**, Butler SM, Tobison J, Boucher EA. Medication Use in Schools: Pediatric Pharmacy Association (PPA) Position Statement. *J Pediatr Pharmacol Ther*. 2020; 25(2): 163-166. PMID: 32071592.
Journal Impact Factor: 0.897, Times Cited: 2
Role: conceptualization, design, analysis, writing, critical review, corresponding author

21. Butler SM, Boucher EA, Tobison J, **Phan H**. Medication Use in Schools: Current Status and Best Practices. *J Pediatr Pharmacol Ther*. 2020;25(1):7-24. PMID: 31897071.

- Journal Impact Factor: 0.897, Times Cited: 18
 Role: conceptualization, design, analysis, writing, critical review, corresponding author
20. Hobart* CB, Daines CL, **Phan H**. Developing Future Clinical Pharmacy Leaders in the Interprofessional Care of Children with Special Health Care Needs and Medical Complexity (CSHCN-CMC) in a Pediatric Pulmonary Center. *Children (Basel)*. 2019 Dec 9;6(12). PMID: 31818043.
 Journal Impact Factor: 2.078, Times Cited: 10
 Role: conceptualization, design, analysis, writing, critical review, corresponding author
 19. Hobart* CB, **Phan H**. Pediatric to Adult Health Care Transition (HCT): Current Challenges and Recommended Practices. *Am J Health Sys Pharm*. 2019; 76(19): 1544-1554. PMID: 31532501.
 Journal Impact Factor: 2.7, Times Cited: 19
 Role: conceptualization, design, analysis, writing, critical review, corresponding author
 18. Stultz JS, Knoderer CA, Manasco KB, Morgan JA, **Phan H**. Identification of factors associated with the desire to participate in a pediatric pharmacy practice-based research network. *J Pediatr Pharmacol Ther*. 2018;23(6): 485-491. PMID: 30697134.
 Journal Impact Factor: 0.897, Times Cited: 5
 Role: conceptualization, design, writing, critical review
 17. **Phan H**. Treatment complexity in cystic fibrosis (CF): An increasing multifaceted challenge. *Pediatr Pulmonol*. 2018;53(9):1174-1176. PMID: 29856505.
 Journal Impact Factor: 2.7, Times Cited: 3
 Role: conceptualization, writing, corresponding author
 16. Wheatley* CM, Baker SE, Daines CL, **Phan H**, Martinez MG, Morgan WJ, Snyder EM. Influence of the Vibralung Acoustical Percussor on pulmonary function and sputum expectoration in individuals with cystic fibrosis. *Ther Adv Respir Dis*. 2018; 12:1-15. Jan-Dec; 12:1753466618770997. doi: 10.1177/1753466618770997. PMID: 29697011.
 Journal Impact Factor: 3.3, Times Cited: 16
 Role: design, critical review
 15. **Phan H**, Brown MA. Fluticasone Furoate for the Treatment of Childhood Asthma. *Expert Review of Respiratory Medicine*. 2015; 9(4): 391-404. PMID: 26184791.
 Journal Impact Factor: 2.9, Times Cited: 3
 Role: conceptualization, design, analysis, writing
 14. Mueller EW, Bishop JR, Kanaan AO, Kiser TH, **Phan H**, Yang KY. Research Fellowship Programs as a Pathway for Training Independent Clinical Pharmacy Scientists. *Pharmacotherapy*. 2015 Mar;35(3): e13-9. PMID: 25756755.
 Journal Impact Factor: 2.9, Times Cited: 17
 Role: design, writing, critical review
 13. Wheatley* CM, Morgan WJ, Cassuto NA, Foxx-Lupo* WT, Daines CL, Morgan MA, **Phan H**, Snyder EM. Exhaled breath condensate detects baseline reductions in chloride and increases in response to albuterol in cystic fibrosis patients. *Clin Med Insights Circ Respir Pulm Med*. 2013 Dec 10; 7:79-90. PMID: 24367235.
 Journal Impact Factor: 1.0, Times Cited: 8
 Role: design, critical review

12. Patanwala AE, Christich* AC, Jasiak* KD, Edwards CJ, **Phan H**, Snyder EM. Age-related Differences in Propofol Dosing for Procedural Sedation in the Emergency Department. *J Emerg Med.* 2013 Apr 44(4):823-8. PMID: 23333181.
Journal Impact Factor: 1.2, Times Cited: 25
Role: conceptualization, design, critical review

11. Bhatt-Mehta V, Buck ML, Chung AM, Farrington EA, Hagemann TM, Hoff DS, La Rochelle JM, Pettit RS, **Phan H**, Potts AL, Smith KP, Parrish RH 2nd. Recommendations for Meeting the Pediatric Patient's Need for a Clinical Pharmacist: A Joint Opinion of the Pediatrics Practice and Research Network of the American College of Clinical Pharmacy and the Pediatric Pharmacy Association. [Dual Journal Publication] *J Pediatr Pharmacol Ther.* 2012 Jul;17(3):281-91. AND *Pharmacotherapy.* 2013 Feb;33(2):243-51. PMID: 23258972.
Journal Impact Factor (*Pharmacotherapy*): 2.9, Times Cited: 39
Role: design, writing, critical review

10. **Phan H**, Porter K, Nahata M. Prescribing trends for medications in the treatment of adolescents and young adults with Type 2 diabetes mellitus. *J Man Care Pharm.* 2012 Oct;18(8):607-14. PMID: 23127148.
Journal Impact Factor: 3.02, Times Cited: 3
Role: conceptualization, design, writing, critical review

9. Jasiak* KD, **Phan H**, Christich* AC, Edwards CJ, Skrepnek GH, Patanwala AE. Induction dose of propofol for pediatric patients undergoing procedural sedation in the emergency department. *Pediatr Emerg Care.* 2012;28: 440-442. PMID: 22531193.
Journal Impact Factor: 1.602, Times Cited: 27
Role: conceptualization, design, writing, critical review

8. Kennedy MJ, **Phan H**, Benavides S, Potts A, Sorensen S. The role of the pediatric pharmacist in personalized medicine and clinical pharmacogenomics for children. *J Pediatr Pharmacol Ther.* 2011;16(2) 118-122. PMID: 22477836.
Journal Impact Factor: 0.897, Times Cited: 27
Role: design, writing, critical review

7. Traylor* BR, Wheatley* CM, Skrentny* TT, Foxx-Lupo* WT, **Phan H**, Patanwala AE, Morgan WJ, Daines CL, Sprissler R, Snyder EM. Influence of Genetic Variation of the Beta-2-Adrenergic Receptor on Lung Diffusion in Patients with Cystic Fibrosis. *Pulm Pharmacol Ther.* 2011 Oct;24(5):610-6. PMID: 21703359.
Journal Impact Factor: 3.3, Times Cited: 6
Role: design, critical review

6. Warholak TL, Queiruga* C, Roush* R, **Phan H**. Medication error identification rates of pharmacy, medical and, nursing students: A simulation. *Am J Pharm Ed.* 2011;75(2): 1-6. PMID: 21519414.
Journal Impact Factor: 3.3, Times Cited: 54
Role: design, writing, critical review, corresponding author

5. **Phan H**, Leder M, Fishley* M, Moeller* M, Nahata MC. Off-label medication use and adverse drug events in patients in the pediatric emergency department. *Pediatr Emerg Care.* 2010;26(6):424-30. PMID: 20502385.
Journal Impact Factor: 1.602, Times Cited: 43
Role: conceptualization, design, analysis, writing, critical review

4. **Phan H**, Moeller* M, Nahata MC. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. *Drugs*. 2009; 69: 2541-76. PMID: 19943707.
Journal Impact Factor: 13, Times Cited: 60
Role: conceptualization, design, writing, critical review
3. **Phan H**, Casavant MJ, Crockett S, Lee A, Hall M, Nahata MC. Serotonin syndrome following a single 50 mg dose of sertraline in a child. *Clin Toxicol*. 2008; 14: 1-5. PMID: 18608268.
Journal Impact Factor: 3, Times Cited: 30
Role: conceptualization, design, writing, critical review
2. **Phan H**, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. *Paediatr Drugs*. 2008; 10(1): 49-69. PMID: 18162008.
Journal Impact Factor: 3.4, Times Cited: 257
Role: conceptualization, design, analysis, writing, critical review
1. Kaakeh Y, **Phan H**, DeSmet B, Pasko DA, Glenn DK, Stevenson JG. Enhanced photoemission spectroscopy for verification of high-risk intravenous medications. *Am J Health Syst Pharm*. 2008; 65(1): 49-54. PMID: 18159039.
Journal Impact Factor: 2.7, Times Cited: 5
Role: conceptualization, design, analysis, writing, critical review

In Press – None at time of CV update

Submitted – None at time of CV update

In Preparation

Key: *denotes student, resident, or postdoc at the time; N/A=not available

5. **Phan H**, Daines CL, Woo TJ, Psoter KJ, Camick N, Goodman A, Riekert KA. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a real-world, m-Health study in CF clinics. Planned submission to *J Cyst Fibros*.
Journal Impact Factor: 4.8, Times Cited: N/A
Role: conceptualization, design, writing, critical review, corresponding author
4. Robinson* C, Vitou* K, Brown J, King M, **Phan H**. Role and Responsibilities of Pharmacists in the Care of People with Sickle Cell Disease: A Scoping Review. Planned submission to *J Am Coll Clin Pharm*.
Journal Impact Factor: 1.3, Times Cited: N/A
Role: conceptualization, design, critical review, corresponding author
3. Hammoud H*, Shannon C, **Phan H**. A Scoping Review of Pharmacists' Contributions in the Care of Children with Chronic Conditions in Ambulatory Care Clinics. Planned submission to *J Am Coll Clin Pharm*.
Journal Impact Factor: 1.3, Times Cited: N/A
Role: conceptualization, design, writing, critical review, corresponding author

2. Ivy* C, Zhang* R, Marshall V, Nguyen* M, Moore* V, Sabourin A, Thompson AN, Nasr SZ, **Phan H**. Asynchronous, hybrid telemedicine clinical pharmacist visits as part of pediatric cystic fibrosis care. Planned submission to *J Cyst Fibros*.
Journal Impact Factor: 4.8, Times Cited: N/A
Role: conceptualization, design, writing, critical review, corresponding author
1. Chen* A, Robinson* C, Marshall V, Caverly LJ, Filbrun A, Nasr SZ, Phan H. Comparison of admission only versus admission-to-home management of pulmonary exacerbations at a pediatric cystic fibrosis care center. Planned submission to *Pediatr Pulmonol*.
Journal Impact Factor: 2.7, Times Cited: N/A
Role: conceptualization, design, writing, critical review, corresponding author

Books

Key: *denotes student, resident, or postdoc at the time; N/A=not available

Benavides S, **Phan H**, Nahata MC (eds). Pediatric Pharmacotherapy Self-Assessment. 1st Edition. Bethesda: American Society of Health-System Pharmacists. 2014. ISBN: 978-1-58528-424-5.

Book Chapters

Key: *denotes student, resident, or postdoc at the time; N/A=not available

21. Hobart CB, **Phan H**. Allergic Rhinitis. In: Matthias KR, Katz MD eds. Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed. New York: McGraw Hill Medical; 2023. (Note: also authored chapter in 5th edition).
20. Fung* MY, **Phan H**. Acute Asthma Exacerbation. In: Matthias KR, Katz MD eds. Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed. New York: McGraw Hill Medical; 2023. (Note: also authored chapter in 4th (2016) and 5th (2019) Ed).
19. Kadouh* N, **Phan H**. Cystic Fibrosis. In: Matthias KR, Katz MD eds. Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed. New York: McGraw Hill Medical; 2023. (Note: also authored chapter in 3rd (2014), 4th (2016), 5th (2019) Ed).
18. Wardlow LC, **Phan H**. Pediatric Immunizations. In: Matthias KR, Katz MD eds. Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 6th ed. New York: McGraw Hill Medical; 2023. (Note: also authored chapter in 2nd (2012), 3rd (2014), and 4th (2016) Ed).
17. **Phan H**, Daines CL. Cystic Fibrosis. In: Kellerman RD, Rakel D (eds). Conn's Current Therapy 2024. Elsevier. 5th Ed. Philadelphia, PA. (Note: also authored chapter in 1st Ed 2020, 2nd Ed (2021), 3rd Ed (2022), 4TH Ed (2023)).
16. Hobart CB, **Phan H**. Theophylline. In: Murphy JE (ed). Clinical Pharmacokinetics. 7th Edition. Bethesda: American Society of Health-System Pharmacists. 2022: 423-442. (Note: also authored chapter in 5th Ed (2011), 6th Ed (2017)).
15. **Phan H**, Daines MO. 65-Allergic Rhinitis. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., (eds). Pharmacotherapy: Principles and Practice. 6th Ed. New York City: McGraw-Hill. 2021; 1049-1064. (Note: also authored chapter in 5th Ed (2018)).

14. **Phan H**, Pai VB, Nahata MC. 2-Pediatrics. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al., (eds). Pharmacotherapy: Principles and Practice. 6th Ed. New York City: McGraw-Hill. 2021; 15-26. (Note: also authored chapter in 2nd Ed (2010) and 3rd Ed (2013), 4th Ed (2016), 5th Ed (2018)).
13. **Phan H**, Nahata MC. Introduction to Pediatrics. In: Benavides S, Nahata MC (eds). Pediatric Pharmacotherapy. American College of Clinical Pharmacy. 2nd Ed. Lenexa, KS. 2020: 3-17. (Note: also authored chapter in 1st (2013: 3-17).
12. **Phan H**, Kuhn RJ. Cystic Fibrosis. In: Benavides S, Nahata MC (eds). Pediatric Pharmacotherapy. American College of Clinical Pharmacy. 2nd Ed. Lenexa, KS. 2020: 211-233. (Note: also authored chapter in 1st Ed (2013).
11. **Phan H**, Murphy JE. Theophylline. In: Murphy JE (ed). Clinical Pharmacokinetics. 6th Edition. Bethesda: American Society of Health-System Pharmacists. 2017:351-364. (Note: also authored chapter in 5th (2011) Ed).
10. **Phan H**, O'Brien C. Cystic Fibrosis. In Murphy JE, Lee MW (ed). Pharmacotherapy Self-Assessment Program (PSAP) 2016-2018: Pulmonary I. Lenexa: American College of Clinical Pharmacy. 2017; 41-66.
9. **Phan H**, Murphy JE. Theophylline. In: Murphy JE (ed). Clinical Pharmacokinetics. 6th Edition. Bethesda: American Society of Health-System Pharmacists. 2017:351-364. (Note: also authored chapter in 5th (2011) Ed).
8. **Phan H**. Asthma. PPA: Pediatric PharmPrep Advanced Guide (book online). 2nd ed (2016), Memphis, TN: Pediatric Pharmacy Association. (Note: also authored chapter in 1st Ed (2015))
7. Lopliato* AC, **Phan H**, Edwards CJ. Type 1 Diabetes Mellitus: Diabetic Ketoacidosis. In: Katz MD, Matthias KR, Chisholm-Burns MA, (eds). Pharmacotherapy: Principles and Practice Casebook. 4th Ed. New York City: McGraw-Hill. 2016: 189-192. (Note: also authored chapter in 1st (2010), 2nd (2012), and 3rd (2014) Ed).
6. **Phan H**. Cystic Fibrosis. In: Benavides S, Phan H, Nahata MC (eds). Pediatric Self-Assessment. 1st Ed. Bethesda: American Society of Health System Pharmacists. 2014: 36-39.
5. **Phan H**. Respiratory Distress Syndrome and Bronchopulmonary Dysplasia. In: Benavides S, Phan H, Nahata MC (eds). Pediatric Self-Assessment. 1st Ed. Bethesda: American Society of Health System Pharmacists. 2014: 40-42.
4. Even* NM, **Phan H**. Anaphylaxis. In: Benavides S, Phan H, Nahata MC (eds). Pediatric Self-Assessment. 1st Ed. Bethesda: American Society of Health System Pharmacists. 2014: 17-20.
3. Lashkar* MO, **Phan H**. Asthma. In: Benavides S, Phan H, Nahata MC (eds). Pediatric Self-Assessment. 1st Ed. Bethesda: American Society of Health System Pharmacists. 2014: 33-35.
2. Babico* MA, **Phan H**. Toxicology. In: Benavides S, Phan H, Nahata MC (eds). Pediatric Self-Assessment. 1st Ed. Bethesda: American Society of Health System Pharmacists. 2014: 23-26.
1. Whittington Goldstone L, Kennedy AK, Clark JS, **Phan H**. Developing and evaluating clinical pharmacy services. In Chisholm-Burns MA, Vaillancourt AM, Shepherd M (eds). Pharmacy Management, Leadership, Marketing, and Finance. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2012: 199-215.

Letters – None at time of CV update

Invited Platform Presentations/Lectures – International / National

Key: presenter is underlined; # indicates poster presentation in addition to platform presentation

50. Manzi S, Bowen A, **Phan H**. What's Up with Mary Jane? Lunch and Learn Workshop. 2024 North American Cystic Fibrosis Conference. Boston MI. October 2024.
49. **Phan H**. Unveiling a Medication Mask to Reveal a CF De-Diagnosis. Consultation Clinic Session. 2024 North American Cystic Fibrosis Conference. Boston MI. October 2024.
48. **Phan H**. Documentation Must Have's For CF Medications, part of session, Making the Unbearable Bearable: CF Cost of Care Hacks for the Care Team. Discipline Group Session. 2024 North American Cystic Fibrosis Conference. Boston MI. October 2024.
47. Ivy C*, Zhang R*, Marshall V, Nguyen M*, Moore V*, Sabourin A; Thompson AN; Nasr SZ; **Phan H**. Asynchronous, hybrid telemedicine clinical pharmacist visits as part of pediatric cystic fibrosis care. Pharmacist Discipline Research Presentation. 2024 North American Cystic Fibrosis Conference. Boston MI. October 2024. #
Accompanying published abstract: Ivy C*, Zhang R*, Marshall V, Nguyen M*, Moore V*, Sabourin A, Thompson AN, Nasr SZ, **Phan H**. Asynchronous, hybrid telemedicine clinical pharmacist visits as part of pediatric cystic fibrosis care. *J Cys Fibr.* 2024; 23:(S2): S273.
46. **Phan H**, Rosano J, Huntman, Safirstein J, Kormelink L, Seamans E, Shanley L. “Documentation practices of cystic fibrosis pharmacists: an opportunity for discipline-wide quality improvement.” Pharmacist Discipline Research Presentation. 2023 North American Cystic Fibrosis Conference. Phoenix, AZ. November 2023. #
Accompanying published abstract: **Phan H**, Rosano J, Huntman, Safirstein J, Kormelink L, Seamans E, Shanley L. Documentation practices of cystic fibrosis pharmacists: an opportunity for discipline-wide quality improvement. *J Cys Fibr.* 2023; 22:(S1): S229.
45. **Phan H**, “Existing Research on Tetrahydrocannabinol (THC): The Latest Decree on THC.” Symposium Speaker. 2023 North American Cystic Fibrosis Conference. Phoenix, AZ. November 2023.
44. **Phan H**, Rounds J, Blomstedt L, Vozoris N, Dickenson J, Heritage R. “A to Zzzz's: Strategies for CF Sleep Disorders”, “Updates on Sleep Disorders in CF.” Workshop Co-Chair and Speaker. 2022 North American Cystic Fibrosis Conference. Phoenix, AZ. November 2023.
43. **Phan H**, Siracusa C. “Sustaining Daily CF Therapies: Approaches & Understanding of Adherence”. Workshop Co-Chair. 2022 North American Cystic Fibrosis Conference. Philadelphia, PA. November 2022.
42. **Phan H**, Clark R. “Wait There Is More' - Hidden Effects of Highly Effective Modulatory Therapy (HEMT)”. Discipline Session Co-Chair. 2022 North American Cystic Fibrosis Conference. Philadelphia, PA. November 2022.
41. **Phan H**, Nahata MC. “Oh, The Places You'll Go”: Navigating Transformations as a Leader in Your Career.” 2022 Pediatric Pharmacy Association (PPA) Fall Conference. September 23, 2022.

40. **Phan H.** “Partnership in Cystic Fibrosis (CF) Care: Communication and Collaboration When Considering Complimentary Therapies.” Cystic Fibrosis Research Institute. 35th National Cystic Fibrosis Education Conference. July 31, 2022. Virtual.
39. **Phan H,** Daines CL, Green A, Camick N, Goodman A, Woo T, Riekert KA “Feasibility and acceptability of a medication schedule mobile application as part of CF care: a real-world, mHealth study in CF clinics.” 2021 North American Cystic Fibrosis Conference. Virtual. November 2021. #
Accompanying published abstract: **Phan H,** Daines CL, Green A, Camick N, Goodman A, Woo T, Riekert KA. Feasibility and acceptability of a medication schedule mobile application as part of CF care: a real-world, mHealth study in CF clinics. *J Cys Fibr.* 2021; 20(S2): S140.
38. **Phan H.** “The Pharmacist Will See You Now: PharmD Telemedicine Visits in CF Care”. Discipline Session Speaker. 2021 North American Cystic Fibrosis Conference. Virtual. November 2021.
37. **Phan H.** “Caring for CF Patients Across the Continuum” Discipline Session Speaker. 2019 North American Cystic Fibrosis Conference. Nashville, TN. November 2019.
36. **Phan H.** “Not Your Cookie Cutter Case: Complex Case Scenarios in Advanced CF Pharmacotherapy.” Short course leader and faculty. 2019 North American Cystic Fibrosis Conference. Nashville, TN. October 2019.
35. **Phan H, Kuhn RJ.** Myths and Truths of Medication Use in Children.” 2019 American Pharmacists Association (APhA) Annual Meeting. Seattle, WA. March 2019.
34. **Phan H.** “Pharmacogenomic Principles of Cystic Fibrosis and Interstitial Pulmonary Fibrosis.” American College of Clinical Pharmacy (ACCP) Global Conference. Seattle, WA. October 2018.
33. **Phan H.** “Controversial Practices: Helpful or Harmful.” Invited Symposium Speaker. 2018 North American Cystic Fibrosis Conference. Denver, CO. October 2018.
Accompanying published abstract: **Phan H.** Considerations in the safety and efficacy of dietary supplements intended to promote lung health. *Pediatr Pulmonol.* 2018; 53(S2): 65-66.
32. **Phan H.** “Gastroesophageal Reflux in CF.” Short Course: Advanced Pharmacology for the CF Provider. Short course leader and faculty. North American Cystic Fibrosis Conference. Denver, CO. October 2018.
31. **Phan H, Kuhn RJ.** “Do it for the Kids: Off-Label and Specialty Medication Management in Pediatrics.” 2018 American Pharmacists Association (APhA) Annual Meeting. Nashville, TN. March 2018.
30. Bowen AM, McGuire M, Mees L, Davidson R, Celaya* T, Faqeer* Z, Lopez* DJ, Nguyen* C, Ojo T, Daines CL, **Phan H.** “Coproduction in the development and implementation of a behavioral health screening program in a CF care center.” 2017 North American Cystic Fibrosis Conference. Indianapolis, IN. November 2017. #
Accompanying published abstract: Bowen AM, McGuire M, Mees L, Davidson R, Celaya* T, Faqeer* Z, Lopez* DJ, Nguyen* C, Ojo T, Daines CL, **Phan H.** Coproduction in the development and implementation of a behavioral health screening program in a CF care center. *Pediatr Pulmonol.* 2017;52(S47):387. 2017 North American Cystic Fibrosis Conference.
29. **Phan H.** “Sustaining Daily Care.” Clinical Roundtable. 2017 North American Cystic Fibrosis Conference. Indianapolis, IN. November 2017.

28. **Phan H.** “The CF Pharmacist Practice-Based Research Network: 2017 Updates & New Study Ideas.” Session Chair and Speaker. Pharmacist Discipline Session. 2017 North American Cystic Fibrosis Conference. Indianapolis, IN. November 2017.
27. **Phan H.** “To Inhale or Not to Inhale: Insights into Aerosolized Medications in the Pediatric Population.” 2017 American College of Clinical Pharmacy (ACCP) Annual Meeting. Phoenix, AZ. October 2017.
26. **Phan H, Kuhn RJ.** “Best Practices for Pharmacists When Caring for Pediatric Patients.” 2017 American Pharmacists Association (APhA) Annual Meeting. Baltimore, MD. March 2017.
25. **Phan H,** Cruz V, Drake G, McGuire M, Werchan B, Settle P, Werchan A, Campion J, Daines CL. “Redesigning Clinic Workflow to Improve Outpatient Cystic Fibrosis Care.” Invited Platform, Workshop Session. 2016 North American Cystic Fibrosis Conference. Orlando, FL. October 2016. #
Accompanying published abstract: **Phan H,** Cruz V, Drake G, McGuire M, Werchan B, Settle P, Werchan A, Campion J, Daines CL. Redesigning clinic workflow to improve outpatient cystic fibrosis care. *Pediatr Pulmonol.* 2016; 51(S45): 474. 2016 North American Cystic Fibrosis Conference.
24. **Phan H.** “The CF Pharmacist Practice-Based Research Network: 2015-16 Updates & New Study Ideas.” Session Chair and Speaker. Pharmacist Discipline Session. 2016 North American Cystic Fibrosis Conference. Orlando, FL. October 2016.
23. **Phan H.** “To Take or Not to Take: A Practical Approach to Adherence.” Roundtable Session Leader. Annual North American Cystic Fibrosis Conference. Orlando, FL. October 2016.
22. **Phan H, Kuhn RJ.** “Take Good Care: Managing Children’s Medications.” 2016 American Pharmacists Association (APhA) Annual Meeting. Baltimore, MD. March 2016.
21. **Phan H.** “Easier Said Than Done: Adherence.” Clinical Controversies in CF Care, Pharmacist Discipline Session. Session Chair and Speaker. Pharmacist Discipline Session. 2015 North American Cystic Fibrosis Conference. Phoenix, Arizona. October 2015.
20. **Phan H.** “The CF Pharmacist Practice Based Research Network (PBRN): Updates and Brainstorming.” 2015 North American Cystic Fibrosis Conference. Phoenix, Arizona. October 2015.
19. **Phan H.** “Pediatric Pulmonology.” Presented at the 2105 Fall Pediatric Pharmacy Association (PPA) Meeting, Board Certification Board Preparation Course. Houston, Texas. September 2015.
18. **Phan H.** “Patient Safety in Special Populations: A Focus on Drug Dosing in Obesity – Pediatrics.” 2014 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Anaheim, California. December 2014.
17. **Phan H.** “The CF Pharmacist Practice Based Research Network (PBRN).” 2014 North American Cystic Fibrosis Conference. Atlanta, Georgia. October 2014.
16. **Phan H, Kuhn RJ.** “Off-Label Use in the Health System: Focus on Pediatrics.” 2014 American Pharmacists Association (APhA) Annual Meeting. Orlando, Florida. March 2014.
15. Daines CL, Drake G, McGuire M, Parker M, Settle P, Werchan B, **Phan H.** Redesigning inpatient cystic fibrosis care. 2013 North American Cystic Fibrosis Conference. Platform Presentation. Baltimore, MD. October 2013. #
Accompanying published abstract: Daines CL, Drake G, McGuire M, Parker M, Settle P, Werchan B, **Phan H.** Redesigning inpatient cystic fibrosis care. *Pediatr Pulmonol.* 2013;48(S36): 392.

14. **Phan H.** “Cystic Fibrosis (CF) Collaborative Research – Path to a Future Practice Research Based Network for CF Pharmacists.” 2013 North American Cystic Fibrosis Conference. Baltimore, MD. October 2013.
13. **Phan H, Kennedy AK.** “PharmD Curriculum and the Path to Clinical Pharmacy Practice in U.S.” Visiting Professor Lecture to Faculty and Students. Malla Reddy College of Pharmacy. Hyderabad, India. October 2013.
12. **Phan H, Babico MA, Kennedy AK.** “Pediatric Pharmacotherapy.” India Association of Colleges of Pharmacy Annual Meeting. Hyderabad, India. October 2013.
11. **Phan H.** “Little Patients, Big Dilemmas: Updates in Pediatrics.” Session Moderator. 2013 American College of Clinical Pharmacy (ACCP) Annual Meeting. Albuquerque, New Mexico. October 2013.
10. **Phan H.** “Transitioning from PGY2 Resident to PGY2 Preceptor.” 2013 American Society of Health-System Pharmacists (ASHP) Summer Meeting. Minneapolis, Minnesota. June 2013.
9. **Phan H.** “Drug Dosing in Obese Pediatric Patients.” 2013 American Society of Health-System Pharmacists (ASHP) Summer Meeting. Minneapolis, Minnesota. June 2013.
8. **Phan H.** “Pediatrics: Little Patients, Big Rewards.” Student Session. 2013 Pediatric Pharmacy Association (PPA) Annual Conference. Indianapolis, Indiana. May 2013.
7. **Phan H.** “Cystic Fibrosis Drug Therapy for the Non-Pharmacist – Issues and Answers.” Short Course Lecture. 2012 North American Cystic Fibrosis Conference. Orlando, Florida. October 2012.
6. **Phan H.** “Late Breakers: Pediatrics – D is for Deficiency in the PICU.” 2012 American College of Clinical Pharmacy (ACCP) Annual Meeting. Hollywood, Florida. October 2012.
5. **Phan H.** “Drug Dosing in Critically Ill Obese Pediatric Patients.” 2012 American Society of Health-System Pharmacists (ASHP) Summer Meeting. Baltimore, Maryland. June 2012.
4. **Phan H.** “What & Why in Drug Therapy: An International Approach.” 2011 North American Cystic Fibrosis Conference. Orlando, Florida. October 2011.
3. **Phan H, Lee J.** “Pediatrics and Geriatrics: Integration or Specialization in the Curriculum?” 2011 American Association of Colleges of Pharmacy Annual Meeting. San Antonio, Texas. July 2011.
2. **Phan H.** “Cultural Considerations in Clinical Practice.” 2011 Annual Pediatric Pharmacy Association (PPA) Meeting. Memphis, Tennessee. March 2011.
1. **Phan H, Kuhn RJ.** “Drug Toxicity in Cystic Fibrosis (CF): Hepatotoxicity, Other Adverse Effects, and CF Drug Therapy: Risk versus Benefit.” Symposium Session. North American Cystic Fibrosis Conference. Baltimore, Maryland. October 2010.
Accompanying published abstract: **Phan H, Kuhn RJ.** Hepatotoxicity, other adverse effects, and CF drug therapy: risk versus benefit. *Pediatr Pulmonol.* 2010; (45)33: 206-208.

Invited Platform Presentations/Lectures - Regional/State/Local

Key: presenter is underlined

31. **Phan H.** “More to CF Medications Than CFTR Modulators” The University of Florida Pediatric Pulmonary Division. Invited Lecture. April 2022.

30. Popov V, Thiel M, **Phan H.** “Development of an Interprofessional Shared Decision-Making Teaching Tool (IP-SDM-T2).” University of Michigan Health Professions Education Day 2022. Lightning Talk (was also a poster presentation).
29. **Phan H.** “Recent Advances in the Treatment of Cystic Fibrosis (CF)” Tom D. Rowe 70th Annual Pharmacy Lectures. The University of Michigan. Virtual. October 2021.
28. **Phan H.** “Going “Back to Where I Came From”: Reflections of a 1st generation AAPI.” Webinar. The University of Arizona Health Sciences, Department of Equity, Diversity, & Inclusion. May 2021.
27. **Phan H.** “Easier Said Than Done: Easier Said than Done - Adherence: Evidenced Based Approaches and Future Directions.” 2019 Arizona Asthma Coalition Conference. Phoenix, AZ. October 2019.
26. **Phan H.** “Medication Use in Schools: An Update on the Stock Inhaler Program.” 2018 Annual Arizona School Healthcare Conference. Tucson, Arizona. January 2018.
25. **Phan H.** “Partnerships with Patients and Families: Coproduction of Asthma Management.” Arizona Asthma Coalition Conference. Phoenix, AZ. October 2017.
24. **Phan H.** “Asthma management in the school setting.” Amphi School District. Tucson, AZ. April 2017.
23. **Phan H.** “Navigating the Muddy Waters of Drug Interactions in CF Drug Therapy.” 2017 Mountain West Cystic Fibrosis Conference. Birmingham, Alabama. March 2017.
22. **Phan H.** “Medication Use in Schools.” Sunnyside School District. Tucson, AZ. March 2017.
21. **Phan H.** “The role of interprofessional teams in managing asthma & allergy: a panel discussion.” 2016 Arizona Asthma Coalition Conference. Phoenix, AZ. October 2016.
20. **Phan H.** “What’s new on the horizon for management of asthma? An update on biologics in management of asthma.” Clinical Track Session (MD/DO/NP/PA). 2016 Arizona Asthma Coalition Conference. Phoenix, AZ. October 2016.
19. **Phan H.** “The new kids on the block for pharmacists: biologics in management of asthma.” Arizona Asthma Coalition Conference. Pharmacist Track Session. Phoenix, AZ. October 2016.
18. **Phan H.** “Asthma management in the school setting.” Sunnyside School District. Tucson, AZ. August 2016.
17. **Phan H.** “Alternative treatment options for pediatric seizure disorders.” California School Nurse Association Conference. San Jose, CA. April 2016.
16. **Phan H.** “Asthma Pharmacotherapy in Very Young and School-Aged Children.” 49th Annual Southwest Clinical Pharmacy Seminar. Tucson, AZ. February 2016.
15. **Phan H.** “Medications in the School Setting.” 2016 Annual Arizona School Healthcare Conference. Tucson, Arizona. January 2016.
14. **Phan H.** “Pharmacotherapy Therapy Through the Lifespan I: Very Young and School-Aged Children.” 9th Annual Arizona Asthma & Allergy Clinical Conference. Mesa, Arizona. October 2015.

13. **Phan H.** “Side Effects of Inhaled Corticosteroids: Should We Worry?” Presented at the 2015 Annual Arizona School Healthcare Conference. Phoenix, Arizona. February 2015.
12. **Phan H.** “Medication Use in the School Setting.” Presented at the 2014 Annual Region XI School Healthcare Training Event, San Diego, California. June 2014.
11. **Phan H.** “A Breath of Fresh Air: Updates in Pediatric Asthma and Bronchiolitis.” Presented at the 2014 Annual Southwest Clinical Pharmacy Seminar. Tucson, Arizona. March 2014.
10. **Phan H., Hall-Lipsy E.** “Medication Use in School: Clinical & Legal Issues.” 2014 Annual Arizona School Healthcare Conference. Tucson, Arizona. February 2014.
9. **Phan H.** “Medication Adherence in Pediatric Patients.” Grand Rounds at Phoenix Children’s Hospital. August 2013.
8. **Phan H.** “Cystic Fibrosis: Drug Therapy Dilemmas and Interdisciplinary Solutions.” Grand Rounds at Phoenix Children’s Hospital. August 2013.
7. **Phan H.** “Cystic Fibrosis Drug Therapy: A Review.” Presented to physicians, nurses, social workers, and pharmacists. The University of Arizona Pediatric Pulmonary Center. Tucson, Arizona. September 2013.
6. **Phan H.** “Updates in Acute Care and Outpatient Therapy in Pediatric Patients.” Presented at the Arizona Pharmacists Association Annual Meeting. Tucson, Arizona. June 2013.
5. **Phan H.** “Discovering Tomorrow.” Keynote Address, 2012 Lotus Laureate Graduation Convocation. Asian Pacific American Student Affairs, The University of Arizona. Tucson, Arizona. May 2012.
4. **Phan H.** “Controversies about Medications and Asthma: From Literature to Practice.” Presented at the Annual Southwest Clinical Pharmacy Seminar. Tucson, Arizona. March 2012.
3. **Phan H.** “Medication Adherence.” Presented to physicians, nurses, social workers, and pharmacists. The University of Arizona Pediatric Pulmonary Center. Tucson, Arizona. January 2012.
2. **Phan H.** “Pediatric Seizures 101 - Clinical Pearls for the Non-Pediatric Pharmacist.” Presented at the 2010 Arizona Pharmacy Alliance, Health-System Academy Conference. Phoenix, Arizona. April 2010.
1. **Phan H.** “Behavior Issues in Children: Major Depressive Disorder and ADHD.” Presented at the 2009 Annual Southwest Clinical Pharmacy Seminar. Tucson, Arizona. February 2009.

Poster Presentations with Published Abstracts

Key: presenter is underlined, * denotes student, resident, or postdoc at the time

31. Chen A*, Robinson (Hendrickson) C*, Marshall V, Caverly L, Filbrun A, Nasr SZ, **Phan H.** Comparison of admission only versus admission-to-home management of pulmonary exacerbations at a pediatric cystic fibrosis care center. *J Cys Fibr.* 2024; 23:(S2): S497.
30. **Ergenekon A,** Cenk Yanaz M, Guliyeva A, M. Yuksel, Selçuk M, Karabulut S, Metin Cakar N, Uzunoglu B, Tastan G, Kocamaz D, **Phan H,** Gokdemir Y, Erdem Eralp E, Nasr SZ, Karakoc F. Outcomes of cessation of CFTR modulator therapy: an unfortunate experience. *J Cys Fibr.* 2023; 22:(S3): S228-S229. 2023 North American Cystic Fibrosis Conference.

29. Ergenekon A, Cenk Yanaz M, Guliyeva A, M. Yuksel, Selçuk M, Karabulut S, Metin Cakar N, Uzunoglu B, Tastan G, Kocamaz D, **Phan H**, Gokdemir Y, Erdem Eralp E, Nasr SZ, Karakoc F. Outcomes of patients with intermittent versus continuous access to CFTR modulator therapy in Turkey. *J Cys Fibr.* 2023; 22:(S3): S221. 2023 North American Cystic Fibrosis Conference.
28. Enochs C, Filbrun A, Iwanicki C, Moraniec H, Lehrmann J, Stiffler J, Dagher S, Tapley C, **Phan H**, Raines R, Nasr SZ. Development of an interdisciplinary telemedicine care model in a pediatric cystic fibrosis center. *J Cys Fibr.* 2021; 22:(S1): S50. 2021 North American Cystic Fibrosis Conference
28. **Phan H**, Hall-Lipsy E, McCulley K*, Vuong E*, Anderson K*, Sharpe A, Bowen A. Perspectives of people with CF and caregivers regarding medication access and telehealth in CF care during the COVID-19 pandemic. *J Cys Fibr.* 2021; 20(S2): S116. 2021 North American Cystic Fibrosis Conference.
27. **Phan H**, Daines CL, Woo T, Goodman, A, Sawicki GS, Riekert KA. Design And Validation of The CF Medication Questionnaire (CF-MQ). *Pediatr Pulmonol.* 2020; 55(S2): 264. 2020 North American Cystic Fibrosis Conference.
26. Frederick CA, Dunn KM, Green A, Hall S, Lindwall J, Maggs J, Moffett K, **Phan H**, Prickett M, Saavedra MT, Oates GR. Perspectives of The CF Community on Research Ideas Related to Self-Management and Adherence. *Pediatr Pulmonol.* 2020; 55(S2): 271. 2020 North American Cystic Fibrosis Conference.
26. **Phan H**, Aina B, Liu AH, Kobernick A, Bryson D, Lowe AA, Gerald LB, Bender BG. Pharmacists' Contributions in A Community Asthma Program in Navajo Nation, NNR-16.247. *Am J Respir Crit Care Med.* 2020;201:A4280. 2020 American Thoracic Society Conference.
24. Murihead C, Palmrose Q, Condren M, Rotlolo SM, Pettit RS, Gill M, **Phan H**. Survey: Evaluation, Documentation, and Education about Cannabis Use in Cystic Fibrosis. *Pediatr Pulmonol.* 2019; 54(S2):379. 2019 North American Cystic Fibrosis Conference.
23. Seto* D, Romero-Aleshire* J, Eastep* T, Bowen A, Sharpe A, Hall-Lipsy E, **Phan H**. Medication Education in Cystic Fibrosis (CF) Care: Perspectives of Key Stakeholders in the CF Community. *Pediatr Pulmonol.* 2019; 54(S2): 379-380. 2019 North American Cystic Fibrosis Conference.
22. Lam* M, Bradshaw* S, Seto* D, Sharpe A, Jackson K, Hall-Lipsy E, Bowen A, **Phan H**. Use and Perspectives of Complementary Alternative Medicine in the Cystic Fibrosis Community. *Pediatr Pulmonol.* 2019; 54(2): 376. 2019 North American Cystic Fibrosis Conference.
21. Lowe* AA, Gerald JK, Black S, Begay J, **Phan H**, Bender B, Gerald LB. Caregiver Reported Asthma Outcomes of School-Age Navajo Children in Tuba City, Arizona. *Am J Respir Crit Care Med.* 2019; 199:A4071. 2019 American Thoracic Society.
10. Deshpande D, **Phan H**, M. Borgstrom R, Miller, Brown MA. Caregiver knowledge as a predictor of length of stay in children hospitalized with asthma exacerbations [Abstract]. *Ann Allergy Asthma Immunol.* 2018 Nov; 121(5), supplement, S9. 2018 American Academy of Allergy, Asthma, Immunology.
19. **Phan H**, Sawicki GS, Quittner AL, Daines CL, Nasr SZ, Butcher JL, Psoter K, Riekert KA. Medication beliefs among adolescent and adult patients prescribed cystic fibrosis transmembrane protein regulator (CFTR) modulators. *Pediatr Pulmonol.* 2018;53(S2): 425. 2018 North American Cystic Fibrosis Conference.

18. **Phan H**, Hobart* C, Tongchinsub* PP, Daines MO. Combination omalizumab and mepolizumab in an adolescent with severe persistent allergic asthma. *Am J Respir Crit Care Med*. 2018;197:A5577. 2018 American Thoracic Society.
17. Repholz* A, Matthias KR, Sivinski* J, Lew* D, Tien* Q, Daines CL, **Phan H**. Extended infusion of beta-lactams in the treatment of acute pulmonary exacerbations in cystic fibrosis: a pilot evaluation of safety and efficacy outcomes. *Pediatr Pulmonol*. 2017;52 Suppl 47:504. 2017 North American Cystic Fibrosis Conference.
16. Bowen AM, McGuire M, Mees L, Davidson R, Celaya* T, Faqeer* Z, Lopez* DJ, Nguyen* C, Ojo T, Daines CL, **Phan H**. Coproduction in the development and implementation of a behavioral health screening program in a CF care center. *Pediatr Pulmonol*. 2017;52(S47):387. 2017 North American Cystic Fibrosis Conference.
15. Hu* J, Lin* G, Hall-Lipsy H, Phan H Perspectives of rural and non-rural Arizona community pharmacists on pediatric dosing and recommendations. *Pharmacotherapy*. 2017; 37(12): E199. 2017 American College of Clinical Pharmacy Annual Meeting.
14. Miller* TW, Limke* K, Robertson* R, Cash* C, **Phan H**. Evaluation of Medication-Related Risk Factors and Pediatric Hospital Readmissions. *Pharmacotherapy*. 2017; 37(12): E198-199. 2017 American College of Clinical Pharmacy Annual Meeting.
12. Malapit* M, Mallory* EK, Muraalidharan* P, **Phan H**, Hayes Jr. D, Mansour HM. In vitro aerodynamic analysis of co-spray dried fluticasone propionate (FPP) and salmeterol xinafoate (SX) dry powder inhalation aerosols with lactose-alternative excipient. *Am J Respir Crit Care Med*. 2017; 195: A6271. 2017 American Thoracic Society Conference.
11. **Phan H**, Cruz V, Drake G, McGuire M, Werchan B, Settle P, Werchan A, Campion J, Daines CL. Redesigning clinic workflow to improve outpatient cystic fibrosis care. *Pediatr Pulmonol*. 2016; 51(S45): 474. 2016 North American Cystic Fibrosis Conference.
10. **Phan H**, Babico* M, George* A, Foxx-Lupo* WT, Drake RT, Kleifgen B, Daines CL. Pharmacist impact on inpatient drug therapy as part of the interdisciplinary cystic fibrosis team. *Pharmacotherapy*. 2015; 35 (11): E225-226. 2015 American College of Clinical Pharmacy Annual Meeting.
9. Wheatley* CM, Baker SE, Daines CL, **Phan H**, Morgan WJ, Snyder EM. Influence of the vibralong device on Pulmonary function and sputum expectoration in patients with cystic fibrosis. *Pediatr Pulmonol*. 2013;48(S36):357. 2013 North American Cystic Fibrosis Conference.
8. Daines CL, **Phan H**, McGuire M, Parker M, Settle P, Werchan B, Drake G. Impact of a dedicated respiratory care team on inpatient pulmonary outcomes. *Pediatr Pulmonol*. 2013;48(S36):392-393. 2013 North American Cystic Fibrosis Conference.
7. Herko* KK, Guthrie* BT, **Phan H**, Wheatley* CW, Foxx-Lupo* WT, Morgan MA, Daines CL, Morgan WJ, Snyder EM. Genetic Variation of the Beta-2 Adrenergic Receptor and the Bronchodilatory Response to Albuterol in Patients with Cystic Fibrosis. *Pediatr Pulmonol*. 2011 Oct;46 Suppl 34:273. 2011 North American Cystic Fibrosis Conference.
6. Wheatley* CM, Cassuto NA, Foxx-Lupo* WT, **Phan H**, Molina O, Daines CL, Morgan WJ, Snyder EM. Influence of an Inhaled Beta-Agonist on Exhaled Na⁺, K⁺, and Cl⁻ in Patients with Cystic Fibrosis. *Am J Respir Crit Care Med*. 2010;181: A1839. 2010 American Thoracic Society.

5. Wheatley* CM, **Phan H**, Morgan M, Wong EC, Cassuto NA, Foxx-Lupo WT, Daines CL, Morgan WJ, Snyder EM. Pharmacogenetics of the alpha subunit of the epithelial Na⁺ channel on exhaled Na⁺ in response to albuterol in CF. *Pediatr Pulmonol.* 2010;45(33): 287. 2010 North American Cystic Fibrosis Conference.
4. Wheatley* CM, **Phan H**, Wong EC*, Foxx-Lupo WT*, Morgan M, Cassuto NA, Morgan WJ, Daines, CL, Snyder EM. Contribution of DLCO and DLNO measures at rest and peak exercise in explaining variability in changes in outpatient therapy secondary to acute exacerbations in CF. *Pediatr Pulmonol.* 2010; (45)33 :371. 2010 North American Cystic Fibrosis Conference.
3. Traylor* BR, Skrentny* T, Foxx-Lupo* WT, Wheatley* CM, Cassuto NA, **Phan H**, Daines CL, Morgan WJ, and Snyder EM. Influence of an Inhaled B-agonist on Alveolar-Capillary Membrane Conductance and Oxygen Saturation in Patients with Cystic Fibrosis. *Am J Respir Crit Care Med.* 181;2010: A1827. 2010 American Thoracic Society Conference.
2. Cassuto NA, Wheatley* CM, Foxx-Lupo* WT, Patanwala A, **Phan H**, Molina O, Daines CL, Morgan WJ, Snyder EM. Influence of an inhaled β -agonist on exhaled Na⁺, K⁺, and Cl⁻ in humans. *Pediatr Pulmonol.* Supplement 32, 2009:79. 2009 North American Cystic Fibrosis Conference.
1. Cassuto NA, Wheatley* CM, Foxx-Lupo* WT, Patanwala A, **Phan H**, Molina O, Daines CL, Morgan WJ, Snyder EM. Alveolar-capillary membrane conductance and pulmonary capillary blood volume during exercise in patients with cystic fibrosis. *Pediatr Pulmonol.* 2009; 44(S32):388. 2009 North American Cystic Fibrosis Conference.

Poster Presentations without Published Abstracts

Key: presenter is underlined, * denotes student, resident, or postdoc at the time

15. Robinson* C, Kadouh N, **Phan H**. Significant Gastrointestinal-Related Adverse Effects After Change from Ivacaftor to Elexacaftor/Tezacaftor/Ivacaftor. 2024 Pediatric Pharmacy Association Annual Meeting. Minneapolis, MN, May 2024.
14. Kim* A, Thompson AN, Axon R, Sabourin A, Davies M, Shannon C, Nasr SZ, **Phan H**. A Systematic Scoping Review Contributions of Pharmacist and Pharmacy Technicians in Cystic Fibrosis Care. American College of Clinical Pharmacy Global Conference. San Francisco, CA. October 2022.
13. Nguyen* M, Ivy* C, Zhang* R, Thompson AN, Sabourin A, Nasr SZ, **Phan H**. Development and Evaluation of an Asynchronous, Hybrid Pediatric Cystic Fibrosis (CF) Clinical Pharmacy Care Model and CF Pharmacy Scoring (CF-RxS) Tool. Pediatric Pharmacy Association Fall Conference. Columbus, OH. September 2022.
12. **Phan H**, Popov V, Thiel M. Development of an Interprofessional Shared Decision-Making Teaching Tool (IP-SDM-T2). University of Michigan Health Professions Education Day, April 2022. Also Presented at 2022 Nexus Interprofessional Conference (virtual), August 2022.
11. Anderson* K, Gerald LB, Hall-Lipsy E, McCulley* K, Vuong* E, **Phan H**. Pharmacists' Perspectives on Inhaled Bronchodilator Use and Stock Inhaler Access for School-Age Children. Pediatric Pharmacy Association. 2020 Fall Conference. Virtual. September 2020
10. Cooley JH, Cameron CK, Bhattacharjee S, **Phan H**. Helping PharmD Students Develop Self-Awareness: A Longitudinal Approach. AACP School Poster Presentation. AACP Annual Meeting. Nashville, TN. July 2017.

9. **Phan H**, Brown MA. Pharmacist collaborative practice in the management of high-risk pediatric asthma. Professional Poster Presentation, Evaluative Study. American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 2016.<http://www.ashp.org/menu/Events/Conferences/Abstract-Archives>.
8. **Cooley JH**, Bhattacharjee S, **Phan H**. Career Preparation for PharmD Students: From Job Networking to Enhancing Interviewing Skills. AACP School Poster Presentation. AACP Annual Meeting, Anaheim, CA. July 2016.
7. **Weddle* P**, Warholak TL, **Phan H**. Pediatric Education Diagnosis Survey (PEDS): Analyzing Pediatric Education within PharmD Program in the US. Pharmacotherapy. 2013 Pediatric Pharmacy Association Annual Conference. Indianapolis, Indiana. May 2013.
6. **Smith* AV**, Matthias KR, **Phan H**. Evaluating treatment options for NAP1 versus non-NAP1 strains of Clostridium difficile infection among pediatric patients at an academic hospital. Pediatric Pharmacy Association (PPA) Annual Conference. Indianapolis, Indiana. May 2013.
5. **Phan H**, Matthias KR. Gender-Associated Perceptions of Pharmacy Practice Faculty. Original Research Poster Presentation. American Association of Colleges of Pharmacy, Annual Meeting, Chicago, IL, July 2013.
4. **Phan H**, Porter K, Nahata M. Prescribing trends for medications in the treatment of adolescents and young adults with Type 2 diabetes mellitus. Academy Managed Care Pharmacy (ACMP) Educational Meeting. San Antonio, TX. October 2009.
3. **Phan H**, **Griffith J**, Casavant MJ, Nahata MC, Baker SD. Evaluation of zolpidem exposures in the pediatric population. North American Congress of Clinical Toxicology (NACCT) Annual Meeting, Toronto, Ontario, Canada, September 2008.
2. **Phan H**, **Griffith J**, Casavant MJ, Nahata MC, Baker SD. Evaluation of zolpidem exposures in the pediatric population. North American Congress of Clinical Toxicology (NACCT) Annual Meeting, Toronto, Ontario, Canada, September 2008.
1. **Phan H**, Pai VB, Stephens, JS, Puthoff T, Nahata MC. Safety and efficacy of inhaled aminoglycoside in mechanically ventilated premature infants for the treatment of symptomatic Gram-negative bacilli tracheitis. ACCP Annual Meeting. Denver, Colorado. October 2007.

PROFESSIONAL, GRADUATE, AND UNDERGRADUATE TEACHING

DIDACTIC TEACHING:

University of Michigan (2020 – Present)

Course # and Title	Years/ Semesters	Role: Coordinator, Lecturer, Both	Brief Course Description (Topics)	Students: PharmD, NP, Graduate or Undergraduate (#)	Student Contact Hrs.
Pharm 302	FA2023	Both	Personal Development (Personal Vision and Mission; Document Your Professional Self; Workplace Readiness; Time Management; Using Your Strengths	Undergraduate (45)	9

			for Your Dream Job; Conflict Management and Teamwork; Understanding Your Values)		
Pharm 200	FA2023	Lecturer	Science of Medicines (Smaller Patients, Bigger Challenges: Pediatric Drug Development and Clinical Trials; Data Safety Monitoring in Clinical Trials: The What, Why, Who, and How: A Case Study of Advances in Pharmacotherapy and Extended Life Expectancy: Cystic Fibrosis; Off Label Medication Use in Pediatrics: Common Practice vs Controversy)	Undergraduate (70)	6
Pharm 570	SP2024 FA2023	Lecturer	Independent Study (Clinic and Quality Improvement Experiences)	PharmD (1) PharmD (1)	1 1
Pharm 677*	FA2023 FA2022 FA 2021	Lecturer	Pediatric Pharmacotherapy (Pediatric Ambulatory Care)	PharmD (16) PharmD (16) PharmD (27)	1.5 1.5 1.5
Pharm 620	FA2023 FA2022 FA2021	Lecturer	Pharmacotherapeutics I (2021-2023: Asthma, COPD, Allergic Rhinitis, 4 hours 2024-Present: Basic Principles, Dose-Response Relationships, Pediatric Considerations, Drug Use in Pregnancy and Lactation, Asthma, COPD, Allergic Rhinitis, 20 hours)	NP (118) NP (103) NP (144)	4 4 4
Pharm 602	FA2023 FA2022 FA2021	Lecturer	Therapeutic Problem Solving I (Asthma, COPD, Associated Labs and Simulated Patient Interactions)	PharmD (76) PharmD (82) PharmD (82)	9 13.5 13.5
Pharm 730	FA2024 FA2023 FA2022 FA2021	Lecturer	Pediatric or Pulmonary Topics; PharmD Investigation Project Presentations	PharmD (2) PharmD (3) PharmD (2) PharmD (2)	n/a
Pharm 719 Pharm 739	FA2024 FA2023 FA2022	Lecturer	PharmD Investigations (Project Mentor)	PharmD (2) PharmD (3) PharmD (2)	n/a
LHS 680	SP2024 SP2023	Lecturer	Teamwork for Healthcare	Graduate	1.5

FA=Fall Semester, WN=Winter Semester, NP=Nurse Practitioner; LHS = Learning Health Systems

*=Elective Course

PRIMARY, PHARMD INVESTIGATION (PDI) ADVISING

Class of 2026	Katherine Vitou
Class of 2025	Georgia Warmbein Delaney Fornwalt
Class of 2024	Chelsey Ivy Ruixi (Grace) Zhang Noreen Mika

The University of Arizona (2008 – 2020)

Years	Course Role	Topics	Learner Type Class Size
College of Pharmacy, Required Curriculum			
2008 – 2010	PhPr 875c Pathophysiology and Therapeutics II <ul style="list-style-type: none"> Module Coordinator Instructor/Lecturer 	Introduction to Pediatrics, Cystic Fibrosis, Common Pediatric Respiratory Illnesses, Acute Otitis Media, Accidental Exposures, Patent Ductus Arteriosus, Neonatal Sepsis 8 hours	3 rd year PharmD ~80-120 students/class
2009 – 2011	PhPr 812, Nonprescription Medications and Devices <ul style="list-style-type: none"> Instructor/Lecturer 	Pediatrics and Self-Care	2 nd year PharmD ~80-120 students/class
2009 – 2011	PhPr 822, Pharmacology and Pharmaceutical Chemistry <ul style="list-style-type: none"> Case discussion Facilitator 	Case topics varied by year, based on availability	2 nd year PharmD ~80-120 students/class
2009 – 2019	PhPr 814, Preventive Health <ul style="list-style-type: none"> Course Coordinator Instructor/Lecturer 	Immunizations, Adult Prevention/Screenings, and Maternal/Child Health 10 hours	2 nd year PharmD ~80-120 students/class
2009 – 2019	PhPr 805b, Introduction to Pharmacy Practice <ul style="list-style-type: none"> Instructor/Lecturer 	Pediatric Pharmacy Practice 1 hour	1 st year PharmD ~80-120 students/class
2010 –2019	PhPr 875b Pathophysiology and Therapeutics II <ul style="list-style-type: none"> Module Coordinator Instructor/Lecturer 	Pediatrics 101, Drugs and Lactation, Infant Nutrition/Formulas, Autism, Common Pediatric Infectious Diseases, Accidental Exposures, Congenital Heart Disease, Conjunctivitis, Asthma, Enuresis, Cystic Fibrosis (chronic care), Nephrotic Syndrome, Neonatal Sepsis 10 hours	2 nd year PharmD ~80-120 students/class
2016 – 2020	PhPr 875a, Pathophysiology and Therapeutics I <ul style="list-style-type: none"> Module Coordinator Instructor/Lecturer Case discussion Facilitator 	Acute Otitis Media, Pharyngitis, Sinusitis, Pediatric Community Acquired Pneumonia, Cystic fibrosis (acute exacerbation), Bronchiolitis, Croup, Pertussis 8 hours	2 nd year PharmD ~80-120 students/class
2016 – 2020	PhPr 811, Advanced Patient Care <ul style="list-style-type: none"> Instructor/Lecturer 	Asthma 2 hours	3 rd year PharmD 80-100 students/class
2016 – 2020	PhPr 885A, Pharmacokinetics	Pediatrics 2 hours	3 rd year PharmD ~80-120 students/class
2017	PhPr 804, Communication Skills and Human Behavior	Communicating with Children and Caregivers (1 hour)	1 st year PharmD ~80-120 students/class

2019	PhPr 860, Pharmacotherapeutics II (new curriculum)	Asthma (2 hours) Attention Deficit Hyperactivity Disorder (ADHD) (1 hour)	2 nd year PharmD ~80-120 students/class
2019	PhPr 809 Beginning Pharmacy Practice	Pediatric Pharmacy (1 hour)	1 st year PharmD ~80-120 students/class
2019	PCOL 310 Drug Approval: The 3 billion Dollar Bet • Instructor/Lecturer	Clinical Trials – Perspectives of a Clinician and Investigator 1 hour	BSPS Students ~40 students/class
College of Pharmacy, Elective Curriculum			
2014 – 2019	PhPr 828 Pharmacy Health Disparities in the U.S. • Instructor/Lecturer	Maternal & Child Health: Impact of Life Course on Health 1 hour	2 nd and 3 rd year PharmD students ~40 students
2009 – 2011	PhPr 887, Individualized Medicine: Applied Pharmacogenetics for Pharmacy Students • Instructor/Lecturer	Cystic Fibrosis and Asthma 2 hours	2 nd and 3 rd year PharmD students ~40 students
2009 – 2011	PhPr 845, Medication Use and the US Health Care System • Instructor/Lecturer	Pediatrics in the Health-Care System	
School of Sociology, Required Curriculum			
2016	CHS 306, Interprofessional Care I Instructor/Lecturer	Beyond the Pharmacy Counter: Clinical Pharmacy 1 hour	Undergraduate ~100 students/class
College of Medicine, Required Curriculum			
2008 – 2020	MED 821, Life Course Instructor/Lecturer	Introduction to Pediatric Pharmacology 2 hours	2 nd year MD ~100 students/class

BSPS = Bachelor of Science, Pharmaceutical Science

University of Arizona, College of Pharmacy, MCHB PPC TRAINING GRANT TRAINEES:

(Key: Maternal Child Health Bureau (MCHB), Pediatric Pulmonary Center (PPC), Long Term Trainee (LT),
Advanced Medium Term (AMT), Medium Term Trainee (MT))

2010 – 2011	Nicole Even, PharmD (MT).
2011 – 2012	Allison George, PharmD (MT)
2012 – 2013	Anita Nayar, PharmD (MT)
2013 – 2014	Mary Babico, PharmD (MT)
2014 – 2015	Alex Lopilato, PharmD (MT) Tara Warren, PharmD (MT)
2015 – 2016	Richard Haftmann, PharmD (AMT)
2016 – 2017	Ashley Repholz, PharmD (MT)
2017 – 2018	Catherine Hobart, PharmD (LT)
2017 – 2019	Tyler Eastep, PharmD Candidate (LT)
2018 – 2019	Melanie Lam, PharmD (AMT), Stephanie Bradshaw, MS Nutrition Candidate (LT)
2018 – 2020	Kalia Anderson, PharmD Candidate (LT)
2019 – 2020	Elizabeth Vuong, PharmD Candidate (LT) Kathryn McCulley, PharmD Candidate (LT)
2019 – 2020	Collin Strunk, PharmD (AMT)

The Ohio State University, College of Pharmacy (2006 – 2008)

Years	Course Role(s)	Topic(s) # of hours	Learner Type Class Size
Required Curriculum			
2006 – 2008	PH 734D, Clinical Pharmacokinetics • Recitation facilitator	Antimicrobials, Pediatrics 2 hours	2 nd year PharmD ~40 students/class
2006 – 2008	PH 781, Pathophysiology and Therapeutics V • Case Facilitator	Endocarditis, Meningitis 4 hours	3 rd year PharmD ~80-120 students/class
2006 – 2008	PH 782, Pathophysiology and Therapeutics VI • Instructor/Lecturer	Cystic Fibrosis 2 hours	3 rd year PharmD ~80-120 students/class
2006 – 2008	PH 617, Introduction to Research • Instructor/Lecturer	Challenges in Pediatric Research 1 hour	2 nd year PharmD ~80-120 students/class
Elective Curriculum			
2006 – 2008	PH 715, Pediatric Pharmacotherapy • Instructor/Lecturer	Major Depressive Disorder in Children/Adolescents, Pediatric Immunizations 2 hours	2 nd , 3 rd year PharmD ~40 students/class

GRADUATE STUDENTS:

University of Arizona

2008 – 2013 Courtney Wheatley, PhD (Graduate Dissertation Committee Member)

RESIDENCY AND FELLOWSHIP TEACHING**THE UNIVERSITY OF ARIZONA - COLLEGE OF PHARMACY**

Years	Rotation	# of Learners/Year
Advanced Pharmacy Practice Experience (APPE)		
2008 – 2010	Acute Care Pediatric Pulmonology	4-6
2009 – 2020	Ambulatory Care Pediatric Pulmonology (Cystic Fibrosis and Severe Asthma Clinics)	4-6
2009 – 2020	Academia Elective	1-2

BANNER UMC-TUCSON PHARMACY RESIDENCY PROGRAMS

Years	Rotation	# of Learners/Year
Postgraduate Year 1 (PGY1) Pharmacy Practice Resident		
2008 – 2020	Pharmacy Resident Scholars in Teaching and Learning Program (PRSTL), Program Mentor	1-2
2008 – 2020	Ambulatory Care Pediatric Pulmonology (Cystic Fibrosis and Severe Asthma Clinics)	2-4

2008 – 2020	Academia	1-2
Postgraduate Year 2 (PGY2) Pediatric Pharmacy Resident		
2008 – 2020	Longitudinal, Ambulatory Care Pediatric Pulmonology (Cystic Fibrosis and Severe Asthma Clinics)	1
2008 – 2020	Academia	1
Postgraduate Year 2 (PGY2) Infectious Disease Resident		
2008 – 2020	Acute Care, Cystic Fibrosis/Pulmonology	1

RESIDENTS AS RESIDENCY PROGRAM DIRECTOR (RPD)

2010 – 2011	Nicole Even, PharmD (PGY2)
2011 – 2012	Allison George, PharmD (PGY2)
2012 – 2013	Anita Nayar, PharmD (PGY2) Manar Lashkar, PharmD (PGY2)
2013 – 2014	Mary Babico, PharmD (PGY2)
2014 – 2015	Alex Lopilato, PharmD (PGY2) Tara Warren, PharmD (PGY2)

PRIMARY MENTOR, RESIDENT RESEARCH

2008 – 2009	Julie Alford, PharmD (PGY1)
2009 – 2010	Karalea Jasiak, PharmD, BCPS (PGY1)
2010 – 2011	Nicole Even, PharmD (PGY2) Allison George, PharmD (PGY1)
2011 – 2012	Allison George, PharmD (PGY2) Manar Lashkar, PharmD (PGY1)
2012 – 2013	Anita Nayar, PharmD (PGY2) Manar Lashkar, PharmD (PGY2) Mary Babico, PharmD (PGY1) William T. Foxx-Lupo, PharmD (PGY1) Amanda Peck PharmD (PGY1)
2013 – 2014	Mary Babico, PharmD (PGY2)
2014 – 2015	Alex Lopilato, PharmD (PGY2) Tara Warren, PharmD (PGY2) Richard Haftmann, PharmD (PGY1)
2015 – 2016	Richard Haftmann, PharmD (PGY2) Ashley Repholz, PharmD (PGY1)
2017 – 2018	Catherine Hobart, PharmD (PGY2)
2018 – 2019	Melanie Lam, PharmD (PGY2)
2019 - 2020	Collin Strunk, PharmD (PGY2)

THE UNIVERSITY OF ARIZONA, COLLEGE OF MEDICINE

Years	Clinical Teaching	# of Learners/Year
Pediatric Pulmonology Fellowship		
2008 – 2020	Pharmacology/Pharmacotherapy topics: cystic fibrosis pharmacotherapy, inhaler devices, pharmacokinetics, antibiotics for cystic fibrosis exacerbations, unusual pulmonary infections, patient/caregiver medication education <ul style="list-style-type: none"> • Dima Ezmigna, MBBS (2009-2012) • Anunya Hiranrattana, MD (2012 - 2015) • Ali Asseri, MD (2016-2018) • Nasim Khattab, MD (2016 - 2019) • Lauren Benton, MD (2019-2021) 	1-2

Pediatrics Residency Program		
2008 – 2020	Pediatric Pharmacotherapy Clerkship (elective, Primary Preceptor)	1
2008 – 2020	Resident Journal Club, Mentor	1-2
2008 – 2020	Teaching Seminars on topics: <ul style="list-style-type: none"> • Cystic fibrosis pharmacotherapy • Pharmacokinetics in pediatrics • Chronic asthma management, inhaler devices 	Topics presented annually

THE UNIVERSITY OF MICHIGAN, COLLEGE OF PHARMACY:

Years	Rotation	# of Learners/Year
Introductory Pharmacy Practice Experience (IPPE)		
2021 – Present	Ambulatory Care Pediatric Cystic Fibrosis Clinic	4-6
Advanced Pharmacy Practice Experience (APPE)		
2021 – Present	Ambulatory Care Pediatric Cystic Fibrosis Clinic	4-6

UNIVERSITY OF MICHIGAN HEALTH – MICHIGAN MEDICINE:

Years	Rotation	# of Learners/Year
Postgraduate Year 1 (PGY1) Pharmacy Practice Resident		
2021 – Present	Ambulatory Care Pediatric Cystic Fibrosis Clinic	2-4
2021 – Present	Academia	1-2
Postgraduate Year 2 (PGY2) Pediatric Pharmacy Resident		
2021 – Present	Longitudinal, Ambulatory Care Pediatric Cystic Fibrosis Clinic	4-6
2021 – Present	Academia	1

PRIMARY MENTOR, RESIDENT RESEARCH

2023 – 2024	Nour Kadouh, PharmD (PGY2) Angela Chen, PharmD (PGY1)
2022 – 2023	Valerie Moore, PharmD (PGY1)
2021 – 2022	Michelle Nguyen, PharmD (PGY1)

PRIMARY MENTOR, RESIDENT WRITING PROJECT

2022 – 2023	Hannah Hammoud, PharmD (PGY2)
2021 – 2022	Joseph Elijah, PharmD (PGY1)

CHOSEN MENTOR, ALL RESIDENT PROGRAMS

2023 – 2024	Ashlyn Whitesell, PharmD
-------------	--------------------------

CLINICAL SERVICE DEVELOPMENT AND IMPLEMENTATION

Ambulatory Care Pharmacy, Pulmonary-Infectious Diseases Clinic 2022 – Present

C.S. Mott Children’s Hospital, Michigan Medicine

Contributed to the development of clinical pharmacy services and serves as clinical pharmacy specialist as part of the interdisciplinary patient care team (pediatric pulmonary physician, pediatric infectious diseases

physician, and clinical pharmacy specialist) providing specialized care for children with complex pulmonary infections such as non-tuberculosis mycobacterium. Services include antimicrobial regimen management (drug selection/dosing, laboratory monitoring, etc.), adherence assessment/intervention, medication reconciliation, drug information, patient/caregiver education.

Ambulatory Care Pharmacy, Pediatric Cystic Fibrosis Center 2020 - Present

C.S. Mott Children's Hospital, Michigan Medicine

Contributed to the development of clinical pharmacy services and serves as clinical pharmacy specialist as part of the interdisciplinary patient care team in the CF Foundation-Accredited Pediatric CF Center. Services include chronic care management (drug selection/dosing, laboratory monitoring, etc.), adherence assessment/intervention, medication reconciliation, drug information, patient/caregiver education, and outpatient exacerbation management (including medication selection/dosing, laboratory monitoring, etc.). Developed innovative telemedicine clinical pharmacy services offering various visit types including asynchronous routine visits, comprehensive medication education visits, adherence support visits, medication monitoring visits, home intravenous antibiotic follow up visits.

Role of a Pharmacy Technician in Cystic Fibrosis and Asthma Clinic 2016 – 2020

Banner University Medical Center-Tucson, Pediatric Pulmonary Center.

Obtained competitive funding to support pilot of pharmacy technician role in cystic fibrosis clinics (2016-2019 Cycle for CFF Expanding Outpatient Clinical Pharmacy Services Grant), with supplemental support from Banner Specialty Pharmacy. Role expanded to include pediatric asthma and support other medication access in the section of pediatric pulmonology. Demonstrated value through achieved metrics, resulting in clinic nursing/support staff budget to include coverage of this continued position.

Ambulatory Care Pharmacy, Pediatric Severe Asthma Clinic 2014 – 2020

Banner University Medical Center-Tucson, Pediatric Pulmonary Center.

Developed clinical pharmacy services and serves as clinical pharmacy specialist, with a pediatric allergist, social worker, and home care nurse for children at high-risk for asthma related complications based on asthma severity classification or hospitalization events (e.g., admission to the intensive care unit). Different from the general asthma clinic, this clinic allocates additional dedicated time for asthma education, medication management, and home assessment with our home care RN. *Clinic establishment and outcomes evaluation supported by an ASHP New Investigator Grant (2014-2016).*

Inpatient Clinical Pharmacy Consult Service, Adult Pulmonary/CF 2012 – 2020

Banner University Medical Center-Tucson, Diamond Children's

Developed clinical pharmacy services and serves as clinical pharmacy specialist as part of the Adult CF Inpatient Service. Services include patient care rounds, antimicrobial management and pharmacokinetic services, acute care plan development (i.e., therapy selection/dosing, laboratory monitoring, etc.), discharge therapy consults, and patient/caregiver education.

Ambulatory Care Pharmacy, General Pediatric Asthma Clinic 2009 – 2020

Banner University Medical Center-Tucson, Pediatric Pulmonary Center

Developed clinical pharmacy services and serves as clinical pharmacy specialist as part of the Pediatric Pulmonology Asthma Clinics. Services include medication management (chronic disease management including medication selection/dosing, laboratory monitoring, etc.) and adherence assessment and intervention, medication reconciliation, drug information, and patient/caregiver education.

Ambulatory Care Pharmacy, Cystic Fibrosis Clinics 2009 – 2020

Banner University Medical Center-Tucson, Tucson Cystic Fibrosis (CF) Clinic

Developed clinical pharmacy services and serves as clinical pharmacy specialist as part of the interdisciplinary patient care team in the CF Foundation-Accredited CF Center for both adults and pediatric patients. Services include chronic care management (drug selection/dosing, laboratory monitoring, etc.), adherence assessment/intervention, medication reconciliation, drug information, patient/caregiver education, and outpatient exacerbation management (including medication

selection/dosing, laboratory monitoring, etc.). *Recognized by the CF Foundation as one of the first CF Foundation Pharmacist Mentoring Program Sites in 2015.*

Inpatient Clinical Pharmacy Service, Pediatric Pulmonary

2008 – 2020

Banner University Medical Center-Tucson, Diamond Children’s

Developed clinical pharmacy services and serves as clinical pharmacy specialist as part of the Section of Pediatric Pulmonology and Sleep. Services include patient care rounds, antimicrobial management and pharmacokinetic services, acute care plan development (i.e., therapy selection/dosing, laboratory monitoring, etc.), discharge therapy consults and patient/caregiver education.

CLINICAL POST-GRADUATE TRAINING PROGRAM DEVELOPMENT:

Postgraduate Year 2 (PGY-2) Pediatric Pharmacy Residency Program 2009

Banner University Medical Center-Tucson, Diamond Children’s

Developed and lead one of the first PGY-2 Pediatric Pharmacy Residency programs in the Southwest/West. Residents provide clinical pharmacy services to a variety of settings including pediatric intensive care unit, neonatal intensive care unit, general pediatric medicine/surgery unit, hematology/oncology unit, pediatric pulmonary consult service, pediatric infectious diseases consult service, weekend clinical coverage, as well as clinical pharmacy service in Cystic Fibrosis (pediatric and adult) and Pediatric Asthma Clinics. Accredited by the American Society of Health-System Pharmacists in 2010 (continued). Served as Residency Program Director from 2009 to 2015.

CONTRIBUTIONS TO INSTITUTIONAL CLINICAL PROTOCOLS/GUIDELINES/POLICIES:

Banner University Medical Center, Tucson, Arizona

- 2020 Telemedicine Clinic Interprofessional Logistics – Pediatric and Adult CF Clinics
- 2019 CFTR Modulators in Patients with Cystic Fibrosis: Candidate Screening, Dosing, and Monitoring – Update
- 2018 Cystic Fibrosis Pulmonary Exacerbation Scoring Form
- 2017 Pre-Clinic Visit Forms, Pharmacy Technician: medication history review, questions for care team members, reminders for clinic
- 2017 Clinic Intake form and Care Plan form for EMR downtime
- 2016 Pharmacokinetic and Renal Dosing in Pediatric Patients
- 2016 Pancreatic Enzymes in Patients with Cystic Fibrosis
- 2015 CFTR Modulators in Patients with Cystic Fibrosis: Candidate Screening, Dosing, and Monitoring
- 2015 Pediatric Empiric Antimicrobial Card/Guide
- 2014 Inpatient Use of Dornase alfa in Patients with Cystic Fibrosis
- 2014 High Dose Ibuprofen in Patients with Cystic Fibrosis: Candidate Screening, Dosing, and Monitoring
- 2013 Vancomycin Therapeutic Drug Monitoring Using Area Under the Curve (AUC) in Patients with Cystic Fibrosis
- 2013 Aminoglycoside Therapeutic Drug Monitoring in Patients with Cystic Fibrosis
- 2012 Use of Extended Infusion Beta Lactams in Patients with Cystic Fibrosis
- 2010 Inpatient Use of Inhaled Tobramycin in Patients with Cystic Fibrosis

Michigan Medicine, Ann Arbor, Michigan

- 2023 Pediatric CF Mucolytic Step-Down Algorithm
- 2022 Pediatric CF Exacerbation Antibiotic Duration Algorithm
- 2022 Pediatric CF Audiology Screening/Monitoring Guidelines
- 2022 Pediatric CF Annual Labs and Rx Refill Guidelines
- 2022 Pediatric CF Exacerbation Antibiotic Duration Guidelines

- 2021 Pediatric CF Aminoglycoside Lab Draw Nursing Protocol
- 2021 Pediatric New CFTR Modulator Onboarding Processes
- 2021 Pediatric CF Exacerbation Guidelines (collaboration between Pediatric Pulmonary and Infectious Diseases services)
- 2021 Revised Therapeutic Substitution and Lab Ordering Protocol to include PharmD
- 2020 Pediatric CF PharmD Visit Algorithm

EXAMPLES OF CLINICAL IN-SERVICES, INTERPROFESSIONAL EDUCATION:

SIMPLIFY CF Step-Down Therapy Proposed Algorithm. Presented to medical attendings, pulmonary division clinical staff. January 2023.

CF Otolaryngology Guidelines. Presented to medical attendings, pulmonary division clinical staff. April 2022

Asthma Treatment – Medications and Inhaler Devices: Updates. Presented to Faculty, Section of Pediatric Pulmonology, and Sleep. Annually 2008-2020.

Pediatric Asthma Patient Care Processes. Presented to medical residents. Banner University Medical Center-Tucson, Diamond Children’s. Annually 2008-2020.

Cystic Fibrosis Acute Exacerbation Management. Presented to attending physicians and medical residents within the Department of Medicine. Banner University Medical Center-Tucson. Annually 2008-2020.

Cystic Fibrosis Drug Therapy: Updates. Presented to Faculty, Section of Pediatric Pulmonology, and Sleep. Annually 2008-2020.

Cystic Fibrosis Drug Therapy: Pediatric Nursing Considerations in Inpatient Care. Presented to Nursing Staff. Banner University Medical Center-Tucson, Diamond Children’s. Annually 2008-2020.

Cystic Fibrosis Drug Therapy: Adult Nursing Considerations in Inpatient Care. Presented to Nursing Staff. Banner University Medical Center-Tucson, Diamond Children’s. Annually 2008-2020.

PROFESSIONAL SERVICE

NATIONAL/INTERNATIONAL PROFESSIONAL SERVICE:

Leadership, Elected Positions

Board Regent American College of Clinical Pharmacy (ACCP)	2023 – 2026
Immediate Past President and Executive Board Member Pediatric Pharmacy Association (PPA)	2020 – 2021
President and Executive Board Member Pediatric Pharmacy Association (PPA)	2019 – 2020
President-Elect and Executive Board Member Pediatric Pharmacy Association (PPA)	2018 – 2019

Director-at-Large, Board Member (3-year elected term) Pediatric Pharmacy Association (PPA)	2014 – 2017
Secretary (2-year elected term) Pediatric Special Interest Group (SIG) American Association of Colleges of Pharmacy (AACCP)	2013 – 2015
Chair Research Committee Pediatric Pharmacy Association (PPA)	2013 – 2014
Chair Pediatric Practice & Research Network (Pediatric PRN) American College of Clinical Pharmacy (ACCP)	2012 – 2013
Chair-Elect Research Committee Pediatric Pharmacy Association (PPA)	2012 – 2013
Chair-Elect Pediatric Practice & Research Network (Pediatric PRN) American College of Clinical Pharmacy (ACCP)	2011 – 2012

Leadership, Appointed Positions

Appointed Co-Lead Cystic Fibrosis Pharmacy Practice Standards and Models (CF Rx-PSM) Core, Cystic Fibrosis Foundation (CFF) CF Pharmacy/Clinical Pharmacology Alliance for Research and Collaboration (CF-PHARM)	2024 – Present
Appointed Member, FCCP and Credentialing Committee American College of Clinical Pharmacy (ACCP)	2022 – 2023
Appointed Member, AACCP Diversity, Equity, Inclusion and Anti-racism Advisory Panel	2021
Appointed Member, Cystic Fibrosis Foundation Otolaryngology Care Multidisciplinary Consensus Recommendations Cystic Fibrosis Foundation	2020-2022
Appointed Member, Ensuring Albuterol Access in Schools: From Policy to Implementation, Policy Statement Working Group American Thoracic Society (ATS) <ul style="list-style-type: none"> • Implementation Committee, Policy Committee 	2020 – 2021
Co-Chair, Publications and Presentations Committee Success with Therapies Research Consortium, Cystic Fibrosis Foundation	2020 – 2021
Appointed Member, Clinical Practice Affairs Committee B American College of Clinical Pharmacy (ACCP)	2018 – 2019

Appointed Member Community Input Project Workgroup Success with Therapies Research Consortium, Cystic Fibrosis Foundation	2018 –2020
Appointed Member Presentations and Publications Committee Success with Therapies Research Consortium, Cystic Fibrosis Foundation	2018 – 2022
Center Representative, UA Pediatric Pulmonary Center Advocacy Committee Maternal Child Health Bureau (MCHB) Pediatric Pulmonary Centers	2017
Appointed Pharmacist Member (3-year term) Education Committee Cystic Fibrosis Foundation	2016 –2019
Chair Research Committee, Pediatric Practice & Research Network American College of Clinical Pharmacy (ACCP)	2016 – 2017
Chair-Elect Research Committee, Pediatric Practice & Research Network American College of Clinical Pharmacy (ACCP)	2015 – 2016
Center Representative, UA Pediatric Pulmonary Center Sleep Ad Hoc Committee Maternal Child Health Bureau (MCHB) Pediatric Pulmonary Centers Mentor, CF Pharmacist Mentoring Program Cystic Fibrosis Foundation	2015 – 2018
Designated Apprentices: 2015 - Kalen Manasco, PharmD (U of Georgia) 2016 - Joe Sartor, PharmD (U of Texas, Tyler) 2017 - Katie Tu, PharmD (Children’s of Orange County) 2018 - Joshua Wang, PharmD (U of Southern California, Keck) 2019 - Mary Alice Gajo, PharmD (Children’s of Los Angeles) 2023 - Jamie Colucci (Akron Children’s)	2015 – Present
Co-Chair Measurements Working Group Success with Therapies Research Consortium, Cystic Fibrosis Foundation	2015 – 2017
Co-Chair Partnership Working Group Success with Therapies Research Consortium, Cystic Fibrosis Foundation	2014 – 2015
Co-Chair Board Certified Pediatric Pharmacotherapy Specialist (BCPPS) Recertification Program Pediatric Pharmacy Association (PPA)	2014 – 2018
Organization Representative, PPA Specialty Framework Advisory Committee Board of Pharmacy Specialties (BPS)	2014

SCCP Faculty Liaison, The University of Arizona American College of Clinical Pharmacy (ACCP)	2013 – 2020
<ul style="list-style-type: none"> • Faculty Coach/Advisor, ACCP Clinical Pharmacy Challenge (2013 – 2020) <ul style="list-style-type: none"> • Conduct student screening and team selection • Coordinate faculty/preceptor review sessions • 2017 - Top 16 (Nationally) • 2019 - Semifinalist (Nationally) • Faculty Coach/Advisor, ACCP Clinical Research Challenge (2016 – 2020) <ul style="list-style-type: none"> • 2016 - 2nd place (Nationally) • 2017 – Top 20 • 2018 – Finalist 	
Appointed Member Postgraduate Fellowship Training Program Review Committee American College of Clinical Pharmacy (ACCP)	2012 – 2018
Representative, Banner University Medical Center-Tucson UHC Pediatric Committee	2012 – 2015
Chair Travel Award Committee, Pediatric Practice & Research Network American College of Clinical Pharmacy (ACCP)	2011 – 2015
Center Representative, UA Pediatric Pulmonary Center Cultural Sensitivity Committee Maternal Child Health Bureau (MCHB) Pediatric Pulmonary Centers	2010 – 2014

Professional Membership

American Pharmacists Association (APhA) Full Member	2015 – 2020
Association of Teachers of Maternal and Child Health (ATMCH) Faculty/Staff-Academic MCH Training Program Member	2015 – 2020
American Academy of Pediatrics (AAP) Affiliate Member Section of Pediatric Pulmonology & Sleep Medicine (SOPPSM)	2015 – Present
American Thoracic Society (ATS) Full Member	2014 – 2022
American Association of Colleges of Pharmacy (AACCP) Full Member	2009 – Present
Rho Chi Academic Honor Society <ul style="list-style-type: none"> • Postgraduate Member, The Ohio State University (2007-2017) • Faculty Member, The University of Arizona (2017 – 2020) • Faculty Member, The University of Michigan (2020-Present) 	2007 – Present

Pediatric Pharmacy Association (PPA)	2006 – Present
<ul style="list-style-type: none"> • Research Committee (2006 – Present) • Nominations Committee (2018-2019, 2020-2021 (Chair), 2021-2022) • Yaffe Award Selection Committee (2019 – Present) 	
American College of Clinical Pharmacy (ACCP)	2006 – Present
Full Member	
<ul style="list-style-type: none"> • ACCP Pediatrics Practice and Research Network • ACCP Infectious Diseases Practice and Research Network • ACCP Education and Training Practice and Research Network • ACCP Clinical Pharmacy Challenge Item Writer (2012-2015, 2017) • CV Reviewer • Resident/Student Mentor • Abstract Reviewer, Annual Meetings • ACCP Pediatric PRN Awards Committee Member • Faculty Coach/Advisor, ACCP Clinical Pharmacy Challenge for University of Michigan, College of Pharmacy (2022 – Present) 	
American Society of Health-System Pharmacists (ASHP)	2002 – 2018
Full Member	2020 – Present
<u>Scholarly Book/Chapter/Guideline Reviewer</u>	
National Association of School Nurses (NASN)	2021
Medication Administration Clinical Practice Guidelines for the School Setting	
ACCP Critical Care Pharmacotherapy	2015
ACCP Flip Cards, Pharmacotherapy	2014
<u>Editorial Board Appointment</u>	
Journal of Pediatric Pharmacology and Therapeutics (JPPT)	2019 – Present
<u>Peer-Review Journal Referee</u>	
JAMA-Pediatrics	2024 – Present
American Thoracic Society (ATS) Scholar	2024 – Present
Pediatric Allergy, Immunology, and Pulmonology	2018 – Present
Currents in Pharmacy Teaching and Learning	2017
Cochrane Collaboration Reviews, Airways Group	2016 – 2021
Pediatric Pulmonology	2016 – Present
Expert Reviews in Respiratory Medicine	2016 – 2020
Critical Care Nurse	2014 – 2020
Pharmacotherapy	2012 – Present
Clinical Therapeutics	2011 – 2020
Journal of American Pharmacists Association (JAPhA)	2009 – Present
Journal of Pediatric Pharmacology and Therapeutics (JPPT)	2008 – Present
American Journal of Health-System Pharmacy (AJHP)	2008 – Present
<u>Scientific Abstract Reviewer</u>	
NACFC Poster Presentations	2016 -2023
ACCP Annual Meeting	2017
ACCP Virtual Poster Symposium	2017
PPA Annual Spring Conference	2009 – 2023
ASHP Summer and Midyear Meetings	2009 – 2012
ACCP/ESCP International Congress Meeting	2009

Grant Application Reviewer

CF Foundation, Clinical Research Award Plus Concept Proposal and Planning Grant	2024
ASHP Collaborative Care Grant	2021, 2022
Reviewer, Pharmacist RFA Grants Cystic Fibrosis Foundation	2016

Data Safety Monitoring Board, Advisory Board Appointments, and Other Related Service

Medical Affairs Advisory Board Gilead Sciences Inc	2018
Pharmacist Advisory Board Vertex Pharmaceuticals Incorporated	2018, 2019
Disease Education Advisory Board Vertex Pharmaceuticals Incorporated	2016
Appointed Member, Data Safety Monitoring Board (DSMB) Cystic Fibrosis Foundation (CFF)	2015 – Present

National Institutes of Health (NIH) Related Service

Reviewer Best Pharmaceuticals for Children Act (BPCA) Priority List Eunice Kennedy Shriver NICHD at NIH	2011 – 2014, 2019
Reviewer Small Business Innovation Research (SIBR) Phase II Proposals National Institutes of Health (NIH), National Institutes of Drug Abuse (NIDA)	2014
Co-Chair, Pulmonary Workgroup Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics, Obstetric and Pediatric Pharmacology Branch, Eunice Kennedy Shriver National Institute of Child Health, and Human Development (NICHD) at the National Institutes of Health (NIH)	2011 – 2012

Other Professional Service

Commercial Advisory Panel, Consultant Vertex Pharmaceuticals Incorporated	2018 - 2019
Medical Affairs, Consultant Vertex Pharmaceuticals Incorporated	2017
Co-Lead for University of Arizona CF Center Site MedGap Pilot, Cystic Fibrosis Foundation	2016
Training Instructor for University of Arizona CF Center MSL Training on Cystic Fibrosis Vertex Pharmaceuticals Inc.	2016, 2017
Exam Item Writer, Pediatrics Board Certification in Pediatric Pharmacotherapy Specialty (BCPPS) Board of Pharmacy Specialties (BPS)	2014

LOCAL/STATE PROFESSIONAL SERVICE:**Leadership**

<i>Pharmacy Representative</i> Pediatric Immunizations Work Group Michigan Medicine	2023 – 2024
<i>Faculty Executive Representative</i> Susan B. Meister Child Health Evaluation and Research (CHEAR) Center Department of Pediatrics, Medical School The University of Michigan	2023 - Present
<i>Pharmacy Lead</i> Pediatric Cystic Fibrosis Quality Improvement Core Team C.S. Mott Children’s Hospital, Michigan Medicine	2020 – Present
<i>Vice Chair, Board of Directors</i> Arizona Asthma Coalition (AAC)	2018 – 2020
<i>Member, Board of Directors</i> Arizona Asthma Coalition (AAC)	2017 – 2020
<i>Pharmacy Lead</i> Cystic Fibrosis Continuous Quality Improvement Committee Banner University Medical Center	2010 – 2020
<ul style="list-style-type: none"> Contributed to preparation and achievement of renewal of Center Accreditation by the Cystic Fibrosis Foundation 	
<i>Pharmacy Lead</i> Pediatric Asthma Committee Banner University Medical Center	2010 – 2020
<ul style="list-style-type: none"> Contributed to preparation and achievement and maintenance of Gold Seal Certification in Pediatric Asthma by the Joint Commission 	

Professional Membership

Michigan Pharmacists Association, Full Member	2021 – 2024
Arizona Asthma Coalition (AAC), Full Member	2016 – 2020
Arizona Pharmacy Association, Full Member	2008 – 2020

Arizona Health Science Center – The University of Arizona:

Member, Dean Search Committee, College of Pharmacy	2016
--	------

College of Pharmacy Committees – The University of Michigan:

Chair, Experiential Education Subcommittee	2024 – Present
Member, Curriculum and Assessment Committee	2024 – Present
Member, Admissions Committee	2021 - 2024
Member, Honor Council	2021 - Present

College of Pharmacy Committees – The University of Arizona:

Member, Practice Innovation Taskforce	2019
Chair, Professionalism Committee	2018 – 2020
Member, Student Success Seminar Programming Committee	2017 – 2018
Member, Innovations Committee	2016 – 2018
Member, Assessment Committee	2016 – 2018

Member, Department Head Search Committee	2011 – 2012
Chair, Faculty Teaching Research Service Percent Effort Committee	2016 – 2017
Member, Readmissions Committee	2015 – 2020
Member, Admissions Committee	2012 – 2016

Departmental Committees – Pharmacy Practice and Science – The University of Arizona College of Pharmacy:

Member, Faculty Search Committee	2009 – 2013, 2016
Member, Peer Review Committee	2013 – 2015
Ad-Hoc Member, Faculty Status Committee	2012 – 2013
Chair, Residency-Fellowship Preparation Program Committee	2010 – 2019

Other Faculty Contributions College of Pharmacy – The University of Michigan

Faculty Coach – ACCP Clinical Pharmacy Challenge	2022 – Present
Faculty Advisor – LittleVictors, PPA Student Organization	2023 – Present

Other Faculty Contributions College of Pharmacy – The University of Arizona

Faculty Advisor – SCCP, ACCP Student Chapter	2016 – 2020
Faculty Advisor – PediaCATS, PPA Student Chapter	2010 – 2020

Other Committees – Banner University Medical Center-Tucson (BUMC-T):

Chair, PGY2 Pediatric Pharmacy Residency Advisory Committee	2010 – 2015
Member, Pharmacy Quality Improvement Committee	2010 – 2013
Member, Medication Use Subcommittee	2010 – 2013
Member, BUMC-T Residency Programs Advisory Committee	2009 – 2015

Community Service/Outreach

Pharmacist Committee Member Healthy Children, Daycare Providers Pima County Health Department, American Academy of Pediatrics (AAP)	2010 – 2012
Mentor for Undergraduate/Graduate Students Asian American Faculty, Staff and Alumni Association (AAFSAA) The University of Arizona	2009 – 2014
Health Fair Preceptor, Asthma Screenings/Education The University of Arizona College of Pharmacy	2008 – 2019